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Abstract 
Taking into consideration the long duration of standard treatment for Mycobacterium 
tuberculosis (TB), the high prevalence of HIV co-infection and the growing prevalence of 
drug-resistant TB, there is an urgent need for improved treatment approaches for TB and 
HIV. However, there is inadequate information regarding the burden being placed on the 
Department of Health (DOH) systems by the current treatment of patients established on 
Antiretroviral Therapy (ART) who are newly diagnosed with TB, and by their clinical 
management.  
The aim of the study was to determine what proportion of patients established on ART 
were newly diagnosed with TB, and what their clinical and treatment outcomes were in 
different public sector settings in the eThekwini Region, KwaZulu-Natal (KZN). Approval 
for the study was obtained from the Human Research Committee of Stellenbosch 
University and from the Biomedical Research Committee, KZN.  
The study used a retrospective, quantitative, cohort technique at both TB and ART clinics 
at three sites in the eThekwini region, KZN. These sites were DOH clinics and were 
selected as they all had a TB clinic and a DOH-registered ART clinic. The study focused 
on a period of one year prior to a patient established on ART developed TB. The study 
population comprised all TB patients who attended the selected DOH clinics. 
A data collection tool was developed and pilot-tested. A small sample of patient files 
(n=15, representing 2% of the study population) was randomly selected; five from each 
site. The files and data were excluded from the main study.  
A total of 1824 files (579 from the TB clinics and 1245 from the ART clinics) were 
reviewed. The data were captured into an electronic database (EpiData Version 3.3) and 
analyzed using STATA (Version 11.0) with the assistance of a statistician.  
The findings show that of the study sample from the TB clinics (N=579), 78% (454/579) 
were newly diagnosed with TB. Of the new TB cases, 90% (409/454) had pulmonary TB 
and 71% (413/579) were HIV-positive. Nearly 50% (68/137) of the patients had 
commenced ART prior to TB diagnosis and treatment, and 14% (19/137) had commenced 
ART after TB. Of those who commenced ART prior to TB diagnosis and treatment, 29% 
(20/68) had commenced ART more than three months prior to acquiring TB. 
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The findings from the ART clinics show that of the files (N=1245) reviewed, 40% 
(501/1245) had TB, and of these 8% (42/501) developed TB after three months or more of 
ART.  
Missing data in the patient medical files was a major challenge. The lack of recorded data 
about ART in the TB clinics and about TB in the ART clinics suggests suboptimal clinical 
management and poor integration of HIV and TB services. It was therefore not possible to 
derive a combined HIV-TB outcome measure. 
Recommendations to promote and implement the integration of TB and HIV services 
included policy changes and implementation, management and practice suggestions, 
education and training to integrate TB/HIV services  and increase research to identify gaps 
in clinical management and to improve integration of services. 
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Opsomming 
 
Met inagneming van die lang duur van die standaard behandeling vir Mycobacterium 
tuberkulose (TB), hoë voorkoms van MIV-infeksie en die groeiende voorkoms van 
dwelmweerstandige TB, is daar ’n dringende behoefte aan verbeterde 
behandelingbenaderings vir TB en MIV. Daar is egter ’n gebrek aan inligting oor die las 
geplaas op die Departement van Gesondheid (DvG) se stelsels deur die huidige 
behandeling van pasiënte op antiretrovirale terapie (ART) wat gediagnoseer is met TB en 
deur hul kliniese bestuur. 
 
Die doel van die studie was om vas te stel watter persentasie van pasiënte wat  op ART 
gevestig is, wel met TB gediagnoseer is, en wat hul kliniese en behandeling-uitkomste was 
in verskillende openbare-sektorinstellings in die eThekwini-streek, KwaZulu-Natal (KZN). 
Goedkeuring vir die studie is verkry van die Menslike Navorsingskomitee van die 
Universiteit van Stellenbosch en van die Biomediese Navorsingskomitee, KZN. 
 
Die studie het gebruik gemaak van ’n retrospektiewe, kwantitatiewe ‘cohort’-tegniek by 
beide TB en ARB-klinieke op drie plekke in die eThekwini-streek, KZN. Hierdie terreine 
was DvG-klinieke en is gekies omdat hulle almal oor ’n TB-kliniek en 'n DvG- 
geregistreerde ART-kliniek beskik. Die studie het gefokus op ’n tydperk van een jaar voor 
’n pasiënt wat op ART is, TB ontwikkel het. Die studiepopulasie bestaan uit alle TB-
pasiënte wat die geselekteerde DvG-klinieke bygewoon het.  
 
’n Data-insamelinginstrument is ontwikkel en getoets. ’n Klein voorbeeld van die 
pasiëntlêers (n = 15, 2% van die studie bevolking verteenwoordig) is ewekansig gekies: 
vyf uit elke plek, en die data is vervat in ’n elektroniese databasis (EpiData Version 3,3). 
’n Totaal van 1824 lêers (579 in die TB-klinieke en 1245 lêers in die ART-klinieke) is 
ondersoek. Die data is ontleed deur gebruik te maak van Stata (weergawe 11,0) met die 
hulp van ’n statistikus. 
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Die bevindinge toon dat van die studiemonster in die TB-klinieke (N = 579), 78% (454/579) 
met TB gediagnoseer is. Van die nuwe TB-gevalle, het 90% (409/454) pulmonêre TB 
gehad en was 71% (413/579) MIV-positief. Byna 50% (68/137) van die pasiënte het ART 
begin vóór hulle TB-diagnose en -behandeling, en 14% (19/137) ART ná TB. Van dié wat 
ART voor TB-diagnose en -behandeling begin het, het 29% (20/68) meer as drie maande 
voor die opdoen van TB met ART begin. Die bevindinge van die ART-klinieke toon dat van 
die lêers (N = 1245) wat bestudeer is, 40% (501/1245) TB het, en hiervan het 8% (42/501) 
TB na drie of meer maande van ART ontwikkel. 
 
Ontbrekende data in die pasiënt se mediese lêers was ’n groot uitdaging. Die gebrek aan 
aangetekende data oor ART in die TB-klinieke en oor TB in die ART-klinieke dui op 
suboptimale kliniese bestuur en swak integrasie van MIV- en TB-dienste. Dit was dus nie 
moontlik om ’n gesamentlike MIV-TB uitkomsmaatreël af te lei nie. 
 
Aanbevelings om die integrasie van TB- en MIV-dienste te bevorder en te implementer, 
het beleidveranderinge en -implementering ingesluit, asook bestuur- en praktykvoorstelle, 
onderwys en opleiding om TB-/MIV-dienste by DvG-vlak te integreer en meer navorsing 
om gapings in die kliniese bestuur te identifiseer en die integrasie van dienste te verbeter. 
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Clinical outcome: the results of any health care intervention, including the entire range of 
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applied to patients (Patient-Centred Acute Case Training, n.d.).   
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CHAPTER 1 
SCIENTIFIC FOUNDATION OF THE STUDY 
1.1  Introduction 
Chapter 1 provides a brief overview of the rationale for, as well as the aims and objectives 
of, the study. The chapter also introduces the research methodology and the ethical 
considerations applied in the undertaking of the study. Finally, the chapter offers an outline 
of the respective chapters in the thesis.  
 
1.2  Rationale and background literature 
Mycobacterium tuberculosis (TB) is an opportunistic infection of Acquired Immune 
Deficiency Syndrome (AIDS) in Human Immune Virus (HIV)-infected persons (WHO, 2009: 
1). According to El-Sadr and Tsiouris (2008:525), “the marriage of these two deadly 
infections creates huge challenges for patients, communities, and health systems”. 
Individually, TB and HIV are two of the world's greatest ongoing public health threats. In 
combination, the two diseases can be even more devastating. HIV significantly increases 
an individual's chances of reactivation of latent TB infection and progression to active TB 
disease (El-Sadr & Tsiouris, 2008:29). 
 
TB is the major cause of death in individuals infected with HIV, and the combination of 
both illnesses creates treatment challenges for providers. HIV infection progressively 
increases immunodeficiency and susceptibility to infections, especially TB. As the HIV 
infection progresses and CD4 declines, the immune system weakens thus contributing to 
the progress of TB infection to TB disease. In HIV-seronegative patients with TB infection 
only about 10% develop active TB during their lifetime, and in HIV-seropositive patients 
about 50% will develop active TB disease (DOH, 2009:9). 
 
Globally, TB is a significant cause of illness and death, accounting for an estimated 9.27 
million incident cases in 2007. Of these cases, the African region accounts for an 
estimated 31% (WHO, 2009:411). Among the 9.27 million incident cases of TB globally, an 
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estimated 15% were HIV-seropositive and 79% of these were from the African region 
(WHO, 2009:1).  
 
Southern Africa continues to bear the brunt of the global burden of HIV. In 2007, South 
Africa accounted for 31% of the estimated 79% of HIV seropositive TB cases in the African 
region(WHO, 2009:1).The current HIV prevalence amongst antenatal women in South 
Africa shows that KwaZulu-Natal (KZN) has the highest seroprevalence of HIV (DoH, 
2009:9). KZN is the province with the highest HIV burden in South Africa. KZN also has a 
rapidly progressing TB epidemic (DOH, 2009:9). The 2006 statistics in the National 
Tuberculosis Management Guidelines (DOH, 2009:9) show that in KZN the TB (all cases) 
incident rate was 1076/100 000 population and TB prevalence was 907/100 000 
population (DOH, 2009:9). 
 
Since identifying the TB/HIV co-infection epidemic globally, providers have been making 
concentrated efforts to promote the integration of HIV care and treatment into the TB 
programme. In order to deliver integrated HIV and TB treatment, it is important to 
determine the burden placed on the Department of Health (DOH) by people requiring both 
Antiretroviral Therapy (ART) and TB treatment, as well as identifying strategies toward 
improving the clinical management and treatment outcomes of HIV/TB co-infected 
patients. A recent survey carried out by the Medical Research Council of South Africa 
(SAMRC) at several DOH facilities in the eThekwini and uThungulu districts of KZN, 
demonstrated the high percentage of patients co-infected with TB/HIV. The survey found 
that 74% (699/945) of all TB patients either tested HIV-seropositive or were known to be 
seropositive. Of these, 14% were already on ART as per the CD4 requirement of the DOH 
(Dilraj & Rustomjee, 2009). A study undertaken at a hospital in Johannesburg South Africa 
showed that of a total of 467 TB patients counselled, laboratory data were retrievable for 
373. Of this data, 284 (76%) of HIV results were retrieved. 270 (95%) of the 284 TB 
patients had concurrent HIV infection (John, Menezes, Chita, Sanne & Grobusch, 
2007:795)               
 
Despite the widespread availability of TB treatment, TB/HIV co-infected patients in Africa 
had an annual mortality rate of 25% to 40% before the introduction of ART (Mukadi, Maher 
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& Harries, 2001:143). This mortality was attributable to both complications from 
overwhelming TB disease and immunosuppression from advanced HIV disease (Murray, 
Sonnenberg, Shearer & Godfrey-Faussett, 1999:733) . Thus, efforts to reduce mortality in 
TB/HIV-co infected patients must focus on both improving TB treatment completion rates 
and on providing HIV care and ART (Maher, Harries & Getahun, 2005: 734).                    . 
 
HIV and TB co-infection is associated with high mortality rates and one of the main 
challenges is the integration of combined treatment of HIV and TB. Combining HIV and TB 
treatment is critical for reducing the mortality rate and this has been recently confirmed by 
the SAPIT trial (Abdool Karim, Baxter, et al., 2010:808) in which HIV- positive patients with 
TB who initiated ART during TB therapy had a significant reduction in mortality when 
compared with patients who deferred ART until after TB treatment was complete(Abdool 
Karim, Abdool Karim et al. 2010:808). As a result South African DOH guidelines have 
elevated the CD4 count below which TB patients should initiate concomitant ART, from 
200 to 350 cells/mm3 (DOH, 2010:8).  
 
This change in guidelines is also due to mounting evidence that problems of immune-
reconstitution inflammatory syndrome (IRIS), toxicity, drug/drug interaction, and poor 
adherence to treatment have not prevented first line TB-HIV treatment in the form of 
Efavirenz-based ART and short course TB therapy (isoniazid, rifampicin, pyrazinamide 
and ethambutol) from obtaining good clinical outcomes (Novak, Richardson et al. 2012: 
np). However, there are very few data on the outcomes of combining second line ART with 
TB treatment. Second-line ART combines a Protease inhibitor (PI) with two nucleoside 
analogues and patients are switched following signs of virological, immunological or 
clinical failure of first-line therapy. Combining PIs with rifampicin is more problematic as 
the dose of the PI has to be increased, or super boosted with additional ritonavir. These 
increased PI doses are associated with hepatotoxicity and severe gastrointestinal 
intolerability (DOH, 2009:75). 
 
Based on the literature review undertaken for the study, there is a paucity of research 
conducted in South Africa on the clinical outcomes and management of patients on TB 
therapy and second line ART. The number of patients on ART who develop TB remains 
Stellenbosch University  http://scholar.sun.ac.za
CHAPTER 1:  SCIENTIFIC FOUNDATION OF THE STUDY 
 
4 
unclear. Amongst these it is unknown how many are failing ART, and of those failing 
therapy, there are little data on how these patients are being investigated and managed. 
This situation exposes the need to investigate the proportion of all patients with TB who 
were established on ART at the time of diagnosis, and their clinical and treatment 
outcomes. 
 
Taking into consideration the long (six-month) duration of standard TB treatment, the high 
prevalence of HIV co-infection and the growing prevalence of drug resistant TB, there is an 
urgent need for improved, more effective, and integrated approaches for TB and HIV 
treatment. According to the Tuberculosis Strategic Plan for South Africa (DOH, 2009:20) 
the challenge of implementing integrated TB/HIV services lies in the inadequate detail and 
written formal guidelines on how this collaboration is to be achieved. Limited integration of 
services at health facilities is due to inadequate technical support, guidelines and registers 
for monitoring and evaluation of integrated TB and HIV services (DOH, 2009:20). 
 
1.3 Research problem 
The duration of standard TB treatment, coupled with the high prevalence of HIV co-
infection and the growing prevalence of drug resistant TB in South Africa (DOH, 2009:80) 
reveal the urgency for improved, more effective, and integrated approaches for TB and 
HIV treatment. Based on the findings from the literature review, one aspect of TB and HIV 
co-treatment that has not been extensively studied in South Africa is the combination of 
second line ART and TB treatment at the programmatic level. Importantly, there is 
inadequate information as to the number of patients who require second-line ART and TB 
treatment. For example how many patients are there who are established on ART and are 
subsequently diagnosed with TB? Preliminary data obtained from a study conducted by 
the SAMRC suggest this is a significant proportion of all TB cases (Dilraj & Rustomjee, 
2009).  Furthermore, there is inadequate information concerning the clinical management 
and treatment outcomes of these patients and to what extent second-line ART is being 
used.  
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1.4  Significance of the study 
The study was undertaken in the context that the TB epidemic is adding to the burden of 
the existing HIV burden placed on the DOH services (DOH, 2009:9). The study was done 
to evaluate the percentage of patients who develop TB after three months or more of ART, 
and to determine the clinical and treatment outcomes of these patients in order to 
understand the need for better management of patients combining second-line ART with 
rifampicin. The secondary goal was to show the need for integration and closer follow-up 
of clients on ART for early detection and management of TB and the use of second line 
treatment. 
 
1.5  Research question 
The study focused on public health care facilities in the eThekwini Region in KZN. The 
study sought to answer the following questions:  
(a) What proportion of patients with TB were on ART at the time of their TB diagnosis? 
(b) How were these patients, established on ART at time of TB diagnosis, managed at 
both the TB and ART clinics?  
(c) What were the clinical and treatment outcomes of those patients established on ART 
and newly diagnosed with TB? 
 
For the purpose of the study ‘newly diagnosed TB’ was defined as a patient being treated 
for TB for the first time, independent of the diagnostic test, and ‘established on ART’ as 
having taken ART for more than three months consecutively. 
 
1.6 Research aim 
The aim of the study was to determine:  
(a) the proportion of TB patients  established on ART at the time of their TB diagnosis; 
and 
(b)  the clinical and treatment outcomes of these TB patients in different public health care 
facilities in the eThekwini region of KZN. 
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1.7  Research objectives 
The objectives of the study were as follows: 
(a) To determine the proportion of all patients with TB who were established on ART at 
the time of TB diagnosis;  
(b) To establish the clinical characteristics of patients established on ART who were 
newly diagnosed with TB; 
(c) To evaluate the clinical management of patients established on ART who were newly 
diagnosed with TB; and 
(d) To evaluate the TB and HIV treatment outcomes of patients established on ART who 
developed TB. 
 
1.8  Research methodology 
The research methodology applied in the study will be discussed briefly in the following 
subsections: research approach and design, population and sampling, data collection tool, 
pilot test, validity and reliability, data collection, data analysis, and ethical considerations.  
 
1.8.1  Research approach and design 
This was a retrospective cohort study undertaken at both TB and ART clinics at three DOH 
health care facility sites in the EThekwini region in KZN. The study focused on a period up 
to one year prior to commencement of data collection. The rationale for collecting data 
during this timeframe was that it allowed for clinical TB and HIV follow-up and outcome 
data to be collected through an audit of the medical files of patients included in the study 
sample. 
 
1.8.2  Population and sampling 
It was envisaged that due to poor integration of TB and HIV services it would be necessary 
to look at both clinical systems. There were two study populations for the purpose of the 
study corresponding to TB clinics and ART clinics. In TB clinics it was all patients initiating 
TB therapy regardless of diagnosis. In ART clinics it was all TB patients who had received 
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at least three months of ART prior to their diagnosis of TB. Only clinics in the Northern 
region of eThekwini were selected corresponding to the region where the SAMRC has 
well-established collaborative links. There were a total of 115 DOH clinics in the eThekwini 
region that had a TB component, but only 15 (13%) of these provided on-site TB treatment 
and ART initiation. Of these 15 clinics, 3 were located in the Northern region of eThekwini. 
Accordingly, the study included all the clinics (n=3) for data collection.  
 
1.8.3  Sample size 
A statistician from the Biostatistics Department, SAMRC KZN, was consulted to determine 
the appropriate sample size of patient medical files to be selected from the TB and ART 
clinics for audit (there was no direct patient contact in the study). 
 
1.8.3.1  Proportion of TB patients established on ART at the time of TB diagnosis at the TB 
clinic 
It was estimated that 15% of all patients with TB in the eThekwini Region are on ART. This 
information was gained by personal communication from a researcher at the SAMRC 
(Dilraj & Rustomjee, 2009). At the time of communication these data were not published. 
With a 95% confidence level and 5% margin of error, a sample size of 589 was required, 
at a power of 90% to determine the proportion of TB patients on ART at the time of TB 
diagnosis Accordingly, a total minimum of 600 medical files were selected at the TB clinic 
for audit. 
 
1.8.3.2  Proportion of TB patients established on ART at the time of TB diagnosis at the 
ARV clinic 
A combined HIV and TB favourable clinical and treatment outcome at six months was 
adopted as a measure of treatment outcome. It was estimated that 75% of patients would 
have had a favourable TB outcome (cure or completion) and of these 66% would have had 
a favourable HIV outcome (undetectable viral load). Therefore, it was estimated that with a 
combined favourable HIV and TB outcome of 50% and a 7% error, a sample size of 532 
medical files was required for a 95% confidence at a power of 90% to determine treatment 
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outcome in the cohort at the ARV clinic. A total of 1121 patient medical files from the TB 
and ART clinics would thus be sufficient for this purpose.  
 
1.8.4  Inclusion criteria 
1.8.4.1  TB clinic 
The study sampled the medical files of all adult patients diagnosed with TB by symptoms, 
positive sputum smears and cultures and/or chest x-ray, entered onto the TB register, and 
treated at any of the selected sites 12 months prior to initiation of the study and those aged 
15 years and older. 
 
1.8.4.2  ART clinic 
The study sampled the medical files of all adult patients: diagnosed with HIV, entered onto 
the ART register, and treated for TB at any of the selected sites for at least three months 
prior to initiation of TB treatment and those aged 15 years and older. 
 
1.8.5  Exclusion criteria 
1.8.5.1  TB clinic 
The study excluded the medical files of patients: aged less than 15 years; who had more 
than one month’s TB treatment at a different institution and transferred to the study site to 
continue TB treatment and those treated for drug-resistant TB.  
 
1.8.5.2  ART clinic 
The study excluded the medical files of patients aged less than 15 years and those who 
had less than three months of ART at the time of commencing TB treatment. 
 
1.8.6  Data collection tool 
Data were extracted using a structured data collection tool (Appendix 1). The tool was 
developed by the researcher based on the findings from the literature, recommendations 
from experts in the field (Dr Alex Pym, SAMRC KZN, and Dr Frederick Marais, 
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Stellenbosch University). A statistician from SAMRC KZN advised on the study. The data 
captured included demographics, laboratory results (such as sputum smear and culture, 
CD4 and viral load counts) and clinical variables (such as TB symptoms, TB and ART 
treatment, and treatment outcomes at two and six months). 
 
1.8.7  Pilot test 
Prior to the empirical phase, the data collection tool was tested in order to validate its 
applicability. A small sample of patient medical files (n=15), representing 2% of the study 
population was randomly selected; five from each study site and their data captured. 
These clinics were evaluated by the researcher for data available for capture. Subsequent 
changes to the tool and variables were made to ensure appropriate and quality data 
capturing. The manually captured data were entered into an electronic database (EpiData, 
version 3.3) by the researcher, and used by the statistician (Dr Kabera, MRC KZN) to test 
the data analysis method. The validation files and data were excluded from the empirical 
study.  
 
1.8.8  Validity and reliability 
The data collection tool was evaluated for face validity and applicability by means of the 
pilot test. Content validity was supported by findings from the literature and evaluative 
input from experts in the field (Dr Pym, SAMRC and Dr Marais, Stellenbosch University) 
and a statistician of the SAMRC. Table 1 provides an overview of how content validity was 
determined. Face validity was supported by entering the pilot data onto the electronic 
database and testing to see if data collected met the target variable. 
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Table 1: Content validity of the data collection tool 
Study objectives Questions Literature 
   
To determine the proportion of all 
patients with TB who were 
established on ART at the time of 
TB diagnosis. 
 
 Q3-8: HIV/CD4 status 
(Appendix A) 
HIV and TB co-infection is 
associated with high mortality 
rates. One of the main 
challenges is the integration of 
combined treatment of HIV and 
TB in the public sector (Abdool 
Karim,, et al., 2010:808). 
TB epidemic is adding to the 
burden of the existing HIV 
burden placed on the DOH 
services (DOH, 2009:9). 
 
To establish the clinical 
characteristics of patients 
established on ART who were 
newly diagnosed with TB. 
 
Q-8: CD4 and viral loads data of 
TB Patients. 
 
Q-14: Current TB (Appendix A) 
Literature review revealed lack of 
published evidence on the 
clinical characteristics of patients 
established on ART who were 
newly diagnosed with TB. 
In 2009, the government raised 
the CD4 treatment initiation 
threshold from 200 to 350 
cells/mm3, to be in line with the 
latest WHO guidelines (DOH 
2010:4).Initiating treatment below 
350 cells/mm3 was implemented 
on the basis that it would improve 
the mortality rate amongst those 
that were HIV infected. This 
change was implemented and 
substantiated by the SAPIT trial 
(Abdool Karim et al. 2010:808) 
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objectives Questions Literature 
   
To evaluate the clinical 
management of patients 
established on ART who were 
newly diagnosed with TB.  
 
Q-8:  CD4 and Viral loads data.Q-
9:.ARV therapy 
Q-10: TB diagnosis 
Q-11: Sputum collection 
Q-15: TB therapy 
– (Appendix A) 
 
Effective TB management 
requires early detection and 
prompt commencement of 
treatment (DOH,2009:34).The 
aims of TB treatment are to cure 
the client of TB, decrease 
transmission of TB to others, 
prevent drug resistance or 
relapse by ensuring adherence 
and follow up, and prevent 
deaths from TB or its 
complications(DOH,2009:34). 
Literature review revealed lack of 
published evidence on the 
clinical management of patients 
established on ART who were 
newly diagnosed with TB. 
To evaluate the TB and HIV 
treatment outcomes of patients 
established on ART who 
developed TB. 
 
Q-17: Treatment outcome 
(Appendix A) 
 
Literature review revealed lack of 
published evidence on TB and 
HIV treatment outcomes of 
patients established on ART who 
developed TB. 
 
 
Reliability was enhanced by means of the pilot test to ensure capture of all the required 
data to meet the stated objectives. Reliability was further enhanced by the researcher who 
undertook all the data collection and one trained research fieldworker from the SAMRC 
KZN who assisted with file location and return of files. Collection of the medical files 
sampled for the study was systematic to ensure complete data capture. In addition, based 
on data yielded from the pilot test, the statistician evaluated and confirmed the feasibility of 
the data collection tool and the method of data analysis. 
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1.8.9 Data collection 
Data collection was undertaken by the researcher and the research fieldworker at both the 
TB and ART clinics. Using the data collection tool, data were extracted manually from the 
sampled files. Data extraction was done at the site. Prior arrangement was made with the 
site staff to ensure no interference in the sites daily routine and space was allocated to the 
researcher. Extraction was done during site working hours from 08h30 to 16h30. Data 
collection differed as it was dependent on the availability of the file for data collection. 
Some files where archived and lost and the researcher and fieldworker had to search for 
and locate these files. 
 
1.8.10  Data management and analysis 
Quality control and assurance of the data were undertaken by the researcher on a daily 
basis. The completed data collection records were compared against corresponding 
registers and medical files, and missing data and errors corrected immediately.  
 
The collected data were captured into an electronic database (EpiData Version 3.3) by a 
trained data encoder from the SAMRC KZN. Double entry was completed to verify and 
validate the data captured. The database, reflecting the variables and categories of the 
data collection tool, was presented to and approved by the statistician of the SAMRC KZN.   
 
The data were analyzed using STATA (version 11.0) with the assistance of a statistician, 
at the SAMRC KZN. Data were presented in tables for descriptive statistics. Statistics 
reported were proportions and means and standard deviations. The analysis of categorical 
variables is presented using cross tabulations with frequencies and percentages reported. 
 Means and standard deviations were only used to summarize the age distribution of 
participants within each site. 
 
1.8.10.1 Primary outcome 
The following was the main endpoint or outcome of the study.  
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1.8.10.1.1 Proportion of patients established on ART at the time of TB diagnosis 
The proportion of patients established on ART who were newly diagnosed with TB, 
calculated as a proportion of all TB patients on ART for greater than three months at 
initiation of TB treatment.  
 
1.8.10.1.2 Treatment outcome 
The proportion of patients with combined favourable TB and HIV outcomes at six 
months after initiation or on completion of TB treatment. 
 
1.8.10.2  Secondary outcomes 
These outcomes were additional data that were collected for analysis to assess other 
effects and outcomes. 
 
 1.8.10.2.1  Tuberculosis 
The proportion of TB patients established on at least three months of ART at time of 
TB diagnosis: 
• who were smear-positive;  
• tested for HIV; 
• tested for HIV and CD4; 
• with CD4 less than 200/350 on ART, depending on when ART commenced, as per 
the new DOH guidelines;  
• with favourable TB outcomes at two months (e.g. smear conversion); 
• on ART with viral loads and CD4 after diagnosis of TB;  
• on ART with a CD4 above 200 at the time of TB diagnosis;  
•  with documented ART and TB treatment adherence problems. 
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 1.8.10.2.2 HIV 
The  proportion of patients established on at least three months of ART at time of TB 
diagnosis: 
• on TB treatment who switch from first-line ART therapy to second-line ART therapy;  
• whose CD4 was below 200 at the time of TB diagnosis;  
• who had CD4 and viral loads within three months of TB diagnosis;  
• with viral load undetected at the time of TB diagnosis;  
• with an increase in CD4 and decrease in viral load from baseline; 
• on ART with favourable TB outcomes at two and six months;  
• with favourable HIV outcomes as determined by undetectable viral loads at the end 
of TB treatment;  
• annual rated newly diagnosed TB in patients three months after initiating ART 
therapy;  
• Mortality rate in subjects initiated on TB treatment who have been on ART therapy 
for more than three months.  
 
1.9  Ethical considerations 
Ethical approval for the study was obtained from the Human Research Committee of 
Stellenbosch University (Appendix B), Biomedical Research Committee (BREC) of KZN 
(Appendix C), and the Health Research Committee of the DOH KZN (Appendix D). Written 
permission was obtained from the Medical Superintendents of the selected study sites to 
gain access to the clinics and medical files of the patients sampled for the study (Appendix 
E). Permission was granted by means of e-mail or telephonic consent. 
This was a retrospective study with no patient contact. Data were collected from medical 
files and registers. Data collected were identified by study, register numbers and initials. 
No full names were used and there was no link between names and numbers. Since no 
patients were directly involved in the study, application was made and granted for a waiver 
of consent. 
 
Stellenbosch University  http://scholar.sun.ac.za
CHAPTER 1:  SCIENTIFIC FOUNDATION OF THE STUDY
 
15 
Data collection was undertaken at a time and place that did not impede patient care at the 
selected study sites and data were kept securely in a locked filing cabinet at the office of 
the researcher. Any queries or uncertainty about the study by staff was dealt with by the 
researcher who was contactable by cell phone. 
 
1.10  Time fame 
The data collection was completed over a period of six months. 
 
1.11  Chapter outline of the thesis 
Chapter 1: Scientific foundation of the study 
Chapter 1 provides a brief overview of the rationale for, aims and objectives of, and the 
methodology used in, the study.  
Chapter 2: Literature review 
Chapter 2 presents the findings from the literature review. 
Chapter 3: Research methodology 
Chapter 3 describes the research design and methodology applied in the study. 
Chapter 4: Data analysis, interpretation, and discussion 
Chapter 4 describes and discusses the study findings.  
Chapter 5: Conclusion and recommendations 
Chapter 5 summarizes the achievement of the study objectives, discusses certain 
limitations, offers recommendations based on the findings of the study, and draws together 
the final study conclusions. 
 
1.12  Conclusion 
Chapter 1 briefly outlined the issues of TB and HIV epidemic in South Africa and especially 
in KZN. There is inadequate information regarding the burden being placed on the DOH 
systems by the number of patients established on ART who are being treated for newly 
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diagnosed TB. Furthermore, there is inadequate information concerning the clinical 
management and treatment outcomes of these patients. 
 
The main aim of the study was to fully understand the burden and clinical outcome TB and 
HIV has on the current health system in order to make suggestions and recommendations 
with regards to integration of services toward improved clinical management and treatment 
outcomes. 
 
The lack of information demonstrates the need for research which investigates the 
integration of both the HIV and TB services in the DOH centres in order to promote a 
holistic approach to the HIV/TB co-infection epidemic. 
 
Chapter 2 will present findings from a review of the pertinent literature that supports the 
rationale for the study. 
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CHAPTER 2 
LITERATURE REVIEW 
2.1  Introduction 
Chapter 2 presents findings from a review of the pertinent literature relevant to the study. 
The review offers insights into two key areas: The TB and HIV epidemics at both global 
and local levels; and the need for the integration of TB and HIV clinical management to 
improve patient treatment outcomes.  
 
2.2  Selecting and reviewing the literature 
Literature was selected in terms of the conception of the research proposal. The review 
was started at the conception of the research phase and continued until writing the thesis 
so that the study would include the latest, pertinent literature. Literature was identified and 
selected from multiple electronic databases, Pubmed, Cochrane Library, and Google 
Scholar, periodicals, journals, books, e-books and websites (DOH, NIH, WHO).  
The review is drawn from literature on the following:  
• TB and HIV epidemiology at the global level as well as in South Africa and KZN; 
• DOH standards and requirements for the clinical management of HIV and TB;  
• The need for integrated HIV and TB management, treatment and management of TB 
and HIV; and  
• The challenges of integrating the two services. 
 
2.3  Organisation of findings from review of the literature 
The findings from the literature review are described under the following main headings:  
• Clinical overview of TB;  
• Clinical overview of HIV;  
• TB epidemiology at the global level as well as in South Africa and KZN;  
• HIV epidemiology at the global level as well as in South Africa and KZN;  
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• TB/HIV co-infection challenges;  
• Challenges for TB control; and  
• Clinical management of TB, HIV and TB/HIV co-infection. 
 
Referencing throughout the thesis is presented in accordance with the Harvard style 
(Harvard 2009). The findings from the literature for the study are presented below. 
 
2.4  Clinical overview of TB And HIV 
  
2.4.1  TB 
TB is a chronic, progressive infection caused by the tubercle bacilli, Mycobacterium 
tuberculosis (TB) which mainly affects the lungs but may progress to other pART of the 
body e.g. meninges, kidneys, bones and lymph (Brunner, Smeltzer, Bare, Hinkle & 
Cheever, 2009)            
  
2.4.1.1  Pathophysiology 
The onset of TB occurs when a susceptible person inhales the mycobacterium bacilli and 
becomes infected. The bacteria are transmitted through the airways to the alveoli where 
they are deposited and begin to multiply (Brunner, Smeltzer, Bare, Hinkle & Cheever, 
2009).  The bacilli may also be transported via the lymph system to other pART of the 
body. The immune system initiates an inflammatory reaction resulting in the accumulation 
of exudates in the alveoli. Initial infection usually occurs two to ten weeks after exposure. 
Tubercle bacilli initially cause a primary infection, which most often is asymptomatic. In 
most cases, after about three weeks of uninhibited growth, the immune system 
suppresses bacillary replication before symptoms or signs develop. In about 10% of 
immune-competent patients, latent infection develops into active disease (Brunner et al., 
2009:644). 
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2.4.1.2  Transmission 
TB is an airborne infection. Larger droplets settle and smaller droplets remain suspended. 
TB infection results mainly from inhalation of airborne particles and is transmitted from 
person to person by talking, coughing, sneezing and laughing (Basavanthappa, 2008:745) 
2.4.1.3  Risk factors 
A number of factors have been associated with an individual’s risk of infection (Brunner et 
al., 2009:644). These include: 
(a)  the extent of exposure to the infected airborne particles  
(b) personal (genetic) susceptibility to the infection  
(c) close contact with active TB  
(d) immune compromised status, e.g. HIV  
(e) substance abuse  
(f) pre-existing medical conditions e.g. diabetes, chronic renal failure, etc.  
(g) overcrowding and poor housing   
(h) profession, e.g. healthcare workers 
(i) poor infection prevention control at healthcare level. 
 
2.4.1.4  Signs and symptoms 
Common signs and symptoms of TB include fever, cough (can be productive or non 
productive), night sweats, fatigue, weight loss and haemoptysis (Brunner et al., 2009:644). 
Not all patients will present with the above signs and symptoms. Any patient who presents 
with any of the above symptoms warrants further investigation for prompt commencement 
of TB treatment. 
 
2.4.1.5  Diagnosis 
TB is usually diagnosed by detection of mycobacterium either by sputum microscopy, 
culture of sputum or using a nucleic acid amplification test (NAAT). Other tests including 
interferon gamma release assay (IGRA), a Tuberculin skin test, or chest X-Ray, are also 
used in conjunction with physical examination and assessment (DoH, 2009:18). 
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2.4.2  HIV 
HIV infection results from one of two similar retroviruses (HIV-1 and HIV-2) that are 
transmitted through body fluids (blood, seminal fluid and vaginal secretions). These 
viruses destroy CD4+ lymphocytes and impair cell-mediated immunity which increases the 
risk of certain infections and cancers (Basavanthappa, 2008: 317). 
 
2.4.2.1  Pathophysiology 
HIV is a retrovirus that carries its genetic material in the form of RNA. It attaches itself to 
the uninfected CD4 cell surface and fuses with the cell membrane. The viral core contents 
are emptied into the host cell. HIV’s enzyme reverse transcriptase copies the genetic 
material from the RNA to a double stranded DNA. The double-stranded DNA merges with 
the cellular DNA (Provirus). The cell uses the provirus to make new viral proteins and viral 
RNA. These new viral proteins join the viral RNA and create new viral particles. New viral 
particles bud from the cell and start the process all over (Brunner et al., 2009:1821). 
 
2.4.2.2  Transmission 
HIV may be transmitted through unsafe sex (seminal/vaginal fluid), from mother to child 
(breast feeding, transplacental), by drug abuse (sharing of infected needles) and blood 
(blood transfusion, inflammation/breaks in the skin) (Brunner et al., 2009:1821). 
 
2.4.2.3  Risk factors 
The risk factors associated with HIV infection are unsafe sex, multiple sexual partners, 
substance users, poverty (multiple partners for financial gain), poor education (lack of 
knowledge on the HIV epidemic and consequences thereof, and cultural factors (promote 
multiple partners) (Beers & Porter, 2006).           
 
2.4.2.4  Diagnosis 
Diagnosis is made by rapid test at HIV counseling and testing (HCT).This is a finger prick 
blood test that shows positive or negative status. The result is confirmed by the detection 
of antibodies to HIV or by detecting HIV RNA in the blood (DOH, 2009:74). 
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2.4.3  TB epidemiology  
TB epidemiology is the scientific and medical study of the causes and transmission TB and 
distribution in a given population (Dorland, 1901). 
 
2.4.3.1  TB at global level 
TB is known to man since the time of Hippocrates and may even go beyond if one had to 
look at Indian and Chinese literature (Basavanthappa BP, 2008:713). In 1952 anti-TB 
medication was introduced and in combination with vaccines and improving living 
standards, led to a noticeable decrease in and control of TB infection in the US and some 
developing countries (Brunner et al., 2009:643). With the successful implementation and 
progress of vaccine programmes throughout the world there was hope that TB would be 
eliminated. However, by the late 1980s there was a resurgence of TB due to the emerging 
HIV epidemic and multidrug resistant (MDR) TB. The emergence of MDR TB was mainly 
due to failure to complete TB therapy (Dilraj & Rustomjee, 2009). MDR-TB is defined as 
TB disease caused by strains that are resistant, in vitro, to both rifampicin and isoniazid, 
with or without resistance to other drugs (DoH, 2009:80). 
 
The rapidly growing TB epidemic globally, and especially in Africa, creates an immense 
burden compounded by the increasing HIV co-infection rate. In 2011, there were an 
estimated 8.7 million new cases of TB globally (13% co-infected with HIV); 79% of these 
HIV-positive TB cases were in the African Region. In the same time period approximately 
1.4 million people died from TB, including almost one million deaths among HIV-negative 
individuals and 430 000 among people who were HIV-positive (WHO, 2012: 1). 
 
India and China make up for almost 40% of the world’s TB cases. About 60% of cases are 
in the South-East Asia and Western Pacific regions. The African Region has 24% of the 
world’s cases, and the highest rates of cases and deaths per capita (WHO, 2012:2). 
 
2.4.3.2 TB in South Africa 
South Africa ranked fifth out of the 22 WHO-identified high-burden countries as per the 
number of reported TB cases in 2007 (Lonnroth & Raviglione, 2008:481).  The latest 
statistics for the five high-burden countries is shown in Table 1. Since then the WHO 2010 
Stellenbosch University  http://scholar.sun.ac.za
CHAPTER 2:  LITERATURE REVIEW 
 
22 
report places South Africa third on list of the five countries with the largest number of 
incident cases. “Ninety-five per cent of all cases and 99 % of deaths occur in developing 
countries, with the greatest burden being in sub-Saharan Africa” (Lonnroth & Raviglione, 
2008:481). 
 
TB is a major public health problem in South Africa. According to WHO Global TB Report 
2009, South Africa reported nearly 460,000 new TB cases in 2007. The incidence rate was 
an estimated 948 cases per 100,000 population. This is a major increase from 338 cases 
per 100,000 population in 1998 (WHO 2009:7). 
 
Table 2: Estimated epidemiological burden of TB, 2011: all forms 100 000 pop/year 
 
 
Country 
Incidence 
(Includes TB 
in people with 
HIV) 
Prevalence 
(Includes TB in 
people with 
HIV) 
Mortality HIV Prevalence in 
Incident TB (%) 
HIV-Positive 
Incident 
TB Cases 
(No. in 1000’s) 
India 199 346 35 5.2 120 
China 85 119 36 1.7 17 
Indonesia 222 489 48 4.2 20 
Nigeria 204 382 40 26 86 
South Africa 1180 1250 87 66 390 
(WHO 2012:10) 
 
HIV has contributed significantly to the re-introduction and increase in TB both globally and 
especially in Southern Africa. Southern Africa continues to bear the brunt of the global 
burden of HIV as reported below in Table 2. Thirty-five percent of HIV infections and 38% 
of AIDS deaths in Southern Africa occurred in 2007 (WHO 2008:32). In 2007, South Africa 
accounted for 31% of the estimated 79% of HIV positive TB cases in the African region 
(DOH, 2009:10). 
2.4.3.3 TB in KwaZulu-Natal (KZN) 
In 2006, KwaZulu-Natal had the highest total TB caseload, as shown in Table 3, and this 
accounted for 31% of all TB cases nationally (DOH, 2009:9).  KZN in South Africa is the 
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province with the highest HIV burden and a rapidly progressing TB epidemic (DOH, 
2009:9). 
 
Table 3: TB cases in South Africa: 2006 
 All TB 
Cases 
PTB 
Cases 
New 
Smear 
Positive 
PTB 
Cases 
Retreatment
Smear 
Positive 
PTB 
Cases 
Smear
Negative
PTB 
Cases 
No 
Smear
PTB 
Cases
Children
0-7 
years 
EPTB 
Cases 
Incidence
All TB 
cases 
per 
100 ,000
Incidence
PTB 
cases 
per 
100,000
Eastern 
Cape 
48,512 41,558 19,527 8,473 3,615 9,943 2,805 6,954 687 589
Free State 23,374 19,058 9,553 2,840 2,479 4,186 2,295 4,316 789 643
Gauteng 46,093 34,290 20,609 4,188 2,915 6,578 4,155 11,803 501 372
KZN 104,705 88,271 32,855 9,527 20,547 25,342 8,593 16,434 1076 907
Limpopo 17,301 14,118 7,574 1,323 1,305 3,916 1,069 3,183 305 249
Mpumalanga 15,035 13,496 7,216 1,081 859 4,340 7,55 1,539 463 416
North West 28,421 24,519 12,539 2,954 1,764 7,262 2,156 3,902 738 637
Northern 
Cape 
8,631 7,951 3,583 1,482 901 1,986 1,018 680 950 875
Western 
Cape 
49,093 43,296 17,644 8,563 8,366 8,723 6,955 5,797 1,033 911
South 
Africa 
341,165 286,557 131,100 40,431 42,751 72,276 29,801 54,608 720 605 
(DOH,2009: 9) 
 
2.4.4  HIV epidemiology 
The HIV epidemiology will be discussed at the global level and in South Africa as well as in 
KZN. 
 
 
2.4.4.1  Global level and in South Africa 
 
Sub-Saharan Africa is still the largest contributor to the global HIV burden (UNAIDS, 
2010:26). Although the rate of new HIV infections has decreased, the total number of 
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people living with HIV continues to rise. In 2009, South Africa had 22.5 million people living 
with HIV. This was an estimated 68% of the global total (UNAIDS, 2010: 26). 
 
The HIV incidence appears to have peaked in the mid-1990s, with evidence of declines in 
incidence in several countries in sub-Saharan Africa. Between 2001 and 2009, the 
incidence of HIV infection declined by more than 25% in the estimated 22 countries 
(UNAIDS, 2010: 27), but South Africa’s epidemic remains the largest in the world.  
 
2.4.4.2  HIV epidemiology in KZN  
As shown in Table 4 below, despite a decrease from 2006 but KZN still had the highest 
HIV prevalence rate in 2011, based on the prevalence amongst antenatal women in South 
Africa (DOH, 2011:11). 
 
Table 4: HIV prevalence among antenatal women by province, South Africa, 2006 to 2011 
 HIV Prevalence 
2006 
HIV Prevalence
2007 
HIV Prevalence
2008 
HIV Prevalence 
2010 
HIV Prevalence
2011 
Eastern Cape 28.6 28.8 27.6 16.0 16.02 
Free State 31.1 31.5 32.9 19.47 19.58 
Gauteng 30.8 30.5 29.9 16.0 16.09 
KZN 39.1 38.7 38.7 24.59 24.11 
Limpopo 20.6 20.4 20.7 12.9 12.92 
Mpumalanga 32.1 34.6 35.5 23.94 24.11 
North West 29.0 30.6 31.0 18.83 18.89 
Northern Cape 15.6 16.5 16.2 9.2 9.23 
Western Cape 15.1 15.3 16.1 4.72 4.75 
South Africa 29.1 29.4 29.3 17.3 17.3 
(DOH, 2011:11). 
 
2.4.5  TB/HIV co-infection 
It is estimated that more than 65% of all TB patients in Africa are co-infected with HIV, and 
TB is the leading cause of morbidity and mortality among HIV-infected patients. Despite 
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the widespread availability of TB treatment, TB/HIV co-infected patients in Africa had an 
annual mortality rate of 25% to 40% before the introduction of ART therapy (Mukadi, 
Maher & Harries, 2001: 143). This mortality was attributable to complications from 
overwhelming TB disease as well as immunosuppression from advanced HIV disease 
(Murray, Sonnenberg, Shearer & Godfrey-Faussett, 1999:733).                     
 
In 2007, South Africa, with 0.7% of the world's population, had 17% of the global burden of 
HIV infection, and one of the world's worst TB epidemics, aggravated by increasing drug 
resistance and HIV co-infection (Maher & Raviglione, 2005:167)  .Individually, TB and HIV 
are two of the world's greatest on-going public health threats. In combination, the two 
diseases can be even more devastating. HIV significantly increases an individual's 
chances of reactivation of latent TB infection and progression to active TB disease. TB is 
the major cause of death in individuals infected with HIV, and the combination of both 
illnesses creates treatment challenges for providers. Magnifying these challenges even 
further is the fact that much of the burden of TB/HIV co-infection exists in some of the 
world's most resource-limited settings. Concerted efforts are needed to identify effective 
and feasible strategies to manage both conditions in the co-infected patient (El-Sadr & 
Tsiouris 2008:29). 
 
2.4.5.1  Integrated TB/HIV management 
Currently HIV is considered the greatest risk factor for TB infection progressing to disease 
and TB is the most common life threatening opportunistic infection associated with HIV. In 
areas with high rates of HIV, TB is increasing rapidly (DOH, 2009:10).  
 
HIV and TB co-infection is associated with high mortality rates. One of the main challenges 
is the integration of combined treatment of HIV and TB in the public sector ( Abdool Karim, 
Baxter, et al., 2010:808). Integration of HIV and TB treatment is critical in reducing the 
mortality rate and this has been confirmed by the SAPIT trial (Abdool Karim, Abdool Karim, 
Baxter, et al., 2010:808). This study looked at HIV-positive patients on TB treatment who 
initiated ART therapy. This type of management had a significant reduction in mortality, 
compared to patients who deferred ART until after TB treatment was complete. As a result, 
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South African DOH guidelines have elevated the CD4 count from 200 to 350 below which 
TB patients should initiate concomitant ART (DOH, 2008:10). 
 
2.4.6  Challenges of TB Control 
Global TB control is facing major challenges. The main contributory factor is HIV and 
immune system compromise. Due to poor treatment compliance by patients, there is an 
increase in Multi-Drug Resistance (MDR) and Extreme Drug Resistance (XDR) TB. The 
rising HIV and TB rates are increasing the health care burden on an already overburdened 
health system. Poverty and poor access to health care especially in rural areas further 
compound the challenges of TB control and contribute to the increase in MDR and XDR 
(DOH, 2009:10). 
 
In South Africa, poverty and poor access to health care, especially in rural areas, further 
compound the challenges of TB control, and contribute to the increase in MDR and XDR 
(DOH, 2009:10). 
 
Reports produced by the South African National Department of Health have shown that 
health workers in the study sites did not adequately follow up on patients’ progress after 
starting TB treatment due to lack of resources (DOH, 2009:10).  
 
2.4.6.1  WHO targets for global control of TB 
WHO’s goals for global TB control is that the incidence should be falling and prevalence 
and death rates should be halved by 2015. By then at least 70% of incident sputum smear-
positive cases should be detected and treated in DOTS programmes and 85% should be 
successfully treated (WHO 2009:1). 
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2.4.6.2  The South African National Tuberculosis Programme 
The South African National Tuberculosis Programme (DOH, 2009:34) has outlined a 
strategic plan to control the TB growth rate and to meet the Millennium Development 
Goals. 
 
2.4.7  Clinical management  
Effective TB management requires early detection and prompt commencement of 
treatment. The aims of TB treatment are to cure the client of TB, decrease transmission of 
TB to others, prevent drug resistance or relapse by ensuring adherence and follow up, and 
prevent deaths from TB or its complications (DOH,2009:34). 
 
2.4.7.1  TB 
TB treatment at the DOH clinics is adhered to as per the National Tuberculosis 
Management Guidelines. These guidelines have set out standard regimens of treatment 
for patients with TB. The use of standard treatment regimens decreases prescription 
errors, reduces cost, simplifies training, and facilitates access to drugs when patients 
change health facilities. (DOH, 2009:35). 
 
The drugs used in TB treatment as stipulated by the National Tuberculosis Management 
Guidelines are: R-rifampicin, H-isoniazid, Z-pyrazinamide, E-ethambutol and S-
streptomycin. Regimen 1 (standard regimen) is made up of two months of intensive phase 
and four months of continuation phase. Regimen 2 is made up of three months of intensive 
phase and 5 months of continuation-phase (DoH, 2009:35). 
 
2.4.7.1.1  New cases 
A new case is defined as a patient newly diagnosed and never treated for TB in the 
past, or who had taken TB treatment for less than four weeks. Such patients are 
commenced on the standard regimen i.e. months of isoniazid, rifampicin, 
pyrazinamide and ethambutol (HRZE) in the intensive phase and months months of 
isoniazid and rifampicin-4 (HR) in the continuation phase (DOH,2009:35). 
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         2.4.7.1.2  Retreatment cases 
A retreatment case is a TB patient treated for 4 weeks or more in the past, and who 
are diagnosed for TB again due to treatment failure, defaulted treatment or those 
patients that relapse. Such patients are commenced on two months of isoniazid, 
rifampicin, pyrazinamide, ethambutol and streptomycin and 1 month of isoniazid, 
rifampicin, pyrazinamide, and ethambutol in the intensive phase and 5 months of 
isoniazid, rifampicin and ethambutol in continuation phase (DOH, 2009:35). 
 
Effective treatment of TB requires a patient to strictly adhere to the treatment 
regimen. In order to ensure patient adherence there must be adequate health 
infrastructures and access to health facilities for all. Primary health care staff, who 
are specifically TB trained, to work in TB clinics. There should be continuous training 
and update of staff. The level of TB awareness should be raised at primary health 
care and community level by educating patients and family members about TB 
(prevention and cure) and the need to support family/community members infected 
with TB, side-effects of TB medication, adherence and importance of reporting to 
health facility and continuing treatment (DOH,2009:35). 
 
2.4.7.2  HIV 
ART therapy is indicated in the following instances irrespective of CD4 count: 
WHO clinical stage 4, severe HIV-related disorders such as Immune thrombocytopenia, 
thrombotic thrombocytopenia, polymyositis, lymphocytic interstitial pneumonitis and non 
HIV-related disorders, e.g. Malignancies, Hepatitis B, Hepatitis C. ART is also indicated 
when CD4+ counts are below 200 cells/mm3 and between 200 cells/mm3 to 350 cells/mm3. 
Baseline investigations are recommended in all patients prior to initiating ART, These 
include liver function tests (LFT), full blood count (FBC), serum creatinine, urinalysis for 
proteinuria, hepatitis B surface antigen(DoH 2009:8). 
 
ART therapy should only be commenced when patients are fully prepared to commit 
themselves to long-term treatment and to maintaining good adherence and follow up for 
treatment. Patients must attend at least three educational sessions prior to commencing 
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ART therapy. Patients must show knowledge and understanding that ART therapy is a life 
time therapy and adherence is of utmost importance. They must be informed about side 
effects, active depression and substance abuse. Patients must be encouraged to disclose 
their HIV status as this is a contributory factor to adherence (DOH, 2009: 8). 
 
The patients’ attendance to at least three educational sessions is used to establish the 
patients’ commitment to treatment, adherence and follow up. Once a patient is deemed 
ready ART therapy is commenced (DOH, 2009: 8).Table 5 outlines the National guidelines 
for HIV management. 
Table 5: Standardized National ART Regimens for Adults and Adolescents 
1st Line 
All new patients needing 
treatment 
TDF(Tenofovir) +  
3TC(Lamivudine)/FTC(Emtricitabine) 
+ EFV(Efavirenz)/NVP(Nevirapine) 
For TB co-infection EFV is preferred.
For pregnant women or women of 
child-bearing age, not on reliable 
contraception, NVP is preferred. 
Currently on d4T-based 
regimen with no side effects 
d4T(Stavudine) + 3TC + EFV/NVP Remain on d4T if well tolerated. 
Early switch with any toxicity. 
Substitute TDF if at high risk of 
toxicity (high BMI, older, female, TB 
treatment) 
Contraindication to TDF: renal 
disease 
AZT(Zidovudine)+ 3TC +EFV/NVP  
2nd Line 
Failing on a d4T or AZT-based 
1st line regimen 
TDF + 3TC/FTC + 
LPV/r(Lopinavir/Ritonavir) 
Virological failure must be followed 
by intensive adherence management, 
as resuppression is often possible. If 
repeat VL remains >1000 in three 
months despite adherence 
intervention, switch. 
Failing on a TDF-based  
1st line regimen 
AZT + 3TC + LPV/r Virological failure must be followed 
by intensive adherence 
management, as resuppression is 
often possible. If repeat VL remains 
>1000 in 3 months despite 
adherence intervention, switch. 
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Salvage Therapy 
Failing any 2nd line regimen Specialist referral Virological failure on protease 
inhibitors is almost always due to 
non-adherence. 
Intensively exploring and 
addressing issues relating to 
causes of non-adherence will most 
often lead to resuppression. If VL 
remains high, refer where 
possible, but maintain on failing 
regimen. 
(DOH,2009:8) 
 
2.4.7.3  Management of TB patients on ART therapy 
Patients diagnosed with HIV should be educated and counselled health care staff and 
community health workers about the signs and symptoms of TB and the severity of TB/HIV 
co infection. They should be encouraged to present early to the nearest health facility 
when any of the TB symptoms are recognized or suspected. They should encourage other 
community members who present with such symptoms to visit their local health centres for 
a TB/HIV assessment.  All HIV-positive patients with no signs and symptoms of TB, or a 
PTB contact are eligible for TB prophylaxis (DoH, 2009: 71). 
 
The standard regimen for TB preventive therapy is: Adults: Isoniazid (INH) 5 mg/kg/day 
(maximum 300 mg per day) and Vitamin B6 (pyridoxine) 25 mg per day (DoH, 2010:29). 
The national HIV and AIDS Policy Guideline recommends trimethoprim/ 
sulphamethoxazole (cotrimoxazole) 160/800mg (960mg) daily for all HIV-positive adults 
whether they have TB or not. The standardized treatment for HIV management for South 
Africa and when to switch treatment is shown in table 3 (DOH,2010: 20). 
 
Patients who present with TB before commencing ART therapy should complete two to a 
maximum of eight weeks of TB therapy before commencing ART therapy if the patient has 
a CD4 count of less than 350 cells/mm3. ART therapy should be initiated as soon as the 
patient is tolerating their TB therapy and this is usually within 2-4 weeks. Efavirenz-based 
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regimens are generally preferred in patients with active TB, however, other regimens may 
be considered for use by the clinician/specialist. Patients who develop tuberculosis while 
on ART should continue ART throughout the TB treatment phase. Patients on 
Lopinavir/Ritonavir should have their dose doubled slowly over two weeks (to 800/200 mg 
twice a day); all other regimens can be continued unmodified. Continue these changes to 
Lopinavir/Ritonavir until two weeks after completion of TB treatment. These patients must 
be monitored and investigated closely for hepatotoxicity symptoms (DOH 2010:29). 
 
2.4.7.4 Side-effects  
TB therapy and ART carries significant side-effects, and attention by health care workers 
is important to manage patients effectively and holistically. Table 6 outlines some of the 
common side effects experienced with use of TB treatment and ART (DOH, 2009:24). 
 
Table 6. Common shared side-effects of TB and ART 
Side-effects ART Tuberculosis Treatment 
Nausea Didanosine, Zidovudine, 
protease inhibitors 
Pyrazinamide 
Hepatitis Nevirapine, Efavirenz Rifampicin, Isoniazid, 
Pyrazinamide 
Peripheral neuropathy Stavudine, Didanosine Isoniazid 
Rash Nevirapine, Efavirenz Rifampicin, Isoniazid, 
Pyrazinamide 
 
2.5 Conceptual framework 
In 2009 9.4 million incident TB cases were reported globally. An estimated 11–13% of 
incident cases were HIV-positive and the African Region accounted for approximately 80% 
of these cases (WHO, 2010:1). According to the WHO (2010:1) new data from 15 
countries show that efforts by national TB programmes (NTPs) to engage all care 
providers in TB control can be a particularly effective way to increase the Case Detection 
Rate (WHO, 2010:1). 
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Based on the literature review undertaken for the study, there is a paucity of research 
conducted in South Africa on the clinical outcomes and management of patients on TB 
therapy and second line ART. The number of patients on ART who develop TB remains 
unclear. Amongst these it is unknown how many are failing ART, and of those failing 
therapy, there are few data on how these patients are being investigated and managed. 
This situation exposes the need to investigate the proportion of all patients with TB who 
were established on ART at the time of diagnosis, and their clinical and treatment 
outcomes.  
 
Random visits by the researcher during the preparatory phase of the study of DOH 
facilities showed that they had both a TB and a HIV (VCT) clinic that functioned 
independently of each other. Each clinic kept separate files and logs with referral of 
patients across clinics. Those primary Health Care facilities that did not have a dispensary, 
did not initiate ART therapy, so patients with TB requiring ART needed to be referred out 
to be commenced and stabilized on ART and then referred back to the PHC facility for 
follow up management. TB and HIV cannot be treated as separate conditions rather as a 
whole to ensure control is gained of the rapidly progressing epidemic of co-infection 
(Abdool Karim, Churchyard, Abdool Karim & Lawn, 2009:921)  .  
 
In order to control TB in high HIV settings, collaborative TB/HIV programmes need to be 
implemented in South Africa (DoH, 2009: 71). The main objective of TB/HIV programmes 
must be to create a mechanism of collaboration between TB and HIV/AIDS management 
units, thus reducing the burden of TB among people living with HIV/AIDS and reducing the 
burden of HIV among TB patients . 
 
2.6  Conclusion 
This chapter described the literature reviewed in order to support the research question 
and rationale, and to demonstrate the need for the proposed study. It reviews the 
epidemiology of TB, its association with HIV and how TB has been exacerbated by the 
increase in HIV. Despite the stepping up of programmes and changes in guidelines the 
TB/HIV epidemic is still a major issue in South Africa. The various studies and reports 
reviewed in this chapter bring to the fore the need for integration of the two services but to 
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date limited progress has been made in the government institutions in this respect. All the 
trials show association of TB and HIV as the major contributor to the increasing morbidity 
and mortality rates in South Africa and the dire need for the integration of TB and HIV 
management services. 
 
Having identified from the literature review that integration of TB and HIV is essential in 
curbing the TB/HIV scourge the researcher was brought to the realization that: Firstly it is 
not clear currently how many patients on ART develop TB. It is unknown how many of 
these are failing ART and of those failing therapy, there are few data available on how 
these patients are being investigated and managed and this led to the conceptualization 
and aim of the study. The basis of the research proposal is to describe a cohort of patients 
established on ART therapy who develop TB.  The aim is to determine what proportion of 
all tuberculosis patients are established on ART at the time of TB diagnosis, and what their 
clinical and treatment outcomes are in different public sector settings in the EThekwini 
region, KZN.  
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CHAPTER 3 
RESEARCH METHODOLOGY 
3.1  Introduction 
Chapter 3 describes the methodology applied to the study. This chapter gives in depth 
information regarding the methodology used to determine the sample size, collect and 
analyze data required to meet the study objectives. 
 
3.2  Research aim 
The aim of the study was to determine:  
(a) the proportion of TB patients established on ART at the time of their TB diagnosis; and 
(b) the clinical and treatment outcomes of these TB patients in different public health care 
facilities in the eThekwini region of KZN. 
 
3.3  Research objectives 
The objectives of the study were as follows: 
(a) To determine the proportion of all patients with TB who were established on ART at 
the time of TB diagnosis;  
(b) To establish the clinical characteristics of patients established on ART who were 
newly diagnosed with TB; 
(c) To evaluate the clinical management of patients established on ART who were newly 
diagnosed with TB; and 
(d) To evaluate the TB and HIV treatment outcomes of patients established on ART who 
developed TB. 
 
3.4  Research methodology 
The research methodology of the study is described under the following subsections: 
research approach and design; population and sampling; data collection tool; pilot study; 
validity and reliability; data collection; data management and analysis, and Ethical 
considerations.  
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3.4.1  Research approach and design 
A retrospective design was chosen as a suitable design for the study. A retrospective 
study investigates a phenomenon, situation, problem or issue that has happened in the 
past. Usually that which has happened in the past and  based on the data available for that 
period (Kumar,R. 2005:99). In accordance with the study objectives, the chosen study 
design enabled measurement of the management and clinical outcomes of a cohort of 
patients once commenced on TB treatment and ART. The study required review of clinical 
chART and required data three months post-RT to six months post-TB treatment. This 
could only be achieved retrospectively. It was also a feasible and cost-effective means of 
obtaining sufficient data to answer the objectives and managing a large sample size. The 
study focused on a period of one year prior to patients having commenced and been 
established on ART who developed TB. This timeframe allowed for the collection of clinical 
HIV follow-up and outcome data by means of an audit of the medical files of patients 
included in the study sample. 
 
3.4.1.1 Population and sampling 
This section describes the criteria of the study population and sample included in the 
study. 
 
3.4.1.2  Study population 
The study population comprised all TB patients who attended selected DOH clinics in the 
northern part of the eThekwini region in KZN. The reason was that the South African 
Medical Research Council (SAMRC), the place of work of the researcher, had well-
established collaborative links with them. 
 
A total of 115 DOH clinics in the eThekwini region had a TB component. At the time of the 
study, only 13% (n=15) of the clinics provided comprehensive on-site TB treatment and 
ART initiation. Of these 15 clinics, three were located in the Northern region of eThekwini. 
Accordingly, the study included all three clinics since they had a TB clinic and a DOH-
registered ART clinic.  All the clinics served both rural and urban/semi-urban populations.  
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Initially an additional clinic was also included. This additional site only had an HIV clinic, 
and no TB clinic. It was included because of the large number of patients with follow-up for 
ART therapy. However, this site was later excluded from the study because their internal 
Clinics’ Ethical Board declined inclusion on the basis that the clinic did not have sufficient 
numbers to meet the study population requirements. 
 
3.4.1.2.1  Study population in TB Clinics 
According to policy and protocol guidelines set by the DoH (DoH, 2009:22), suspect 
TB patients who present at the Primary Health Care Department are diagnosed by X-
ray and then referred to the TB clinic for further investigation and sputum collection. 
In this study, all TB patients at the clinics were included, regardless of the means of 
TB diagnoses. These included patients: (a) who had started empirically on treatment; 
(b) diagnosed by X-Ray and had been assessed by the clinician and started TB 
treatment; (c) diagnosed by sputum smear (2x positive sputum smear results) and 
who had commenced treatment by the Primary Health Care nurse; (d) TB positive 
patients who had commenced treatment and were entered into a TB register; (e) with 
TB symptoms and negative sputum smear results who were commenced on 
antibiotics and who awaited sputum culture results before commencement of TB 
treatment; (f) on TB treatment (six months) who had been followed up on a weekly 
basis in the intensive phase of treatment (two months) and then monthly during the 
continuation phase (four months); and (g) who were followed up until their TB 
treatment was completed or they were cured (DOH, 2009:22). 
  
From personal observation by the researcher it was noticed that follow up schedules 
could differ at the respective clinics and also could be altered to suit patients’ 
availability, as long as the patient had sufficient TB medication until the next 
scheduled visit.  
 
Some patients were transferred between facilities for continuation of TB treatment. All 
patients that were transferred into the research site, who had more than one month of 
treatment at the former institution were excluded from the study because data on 
commencement of treatment were not obtainable. Patients transferred out of the 
Stellenbosch University  http://scholar.sun.ac.za
CHAPTER 3:  RESEARCH METHODOLOGY
 
37 
clinic after initiation of therapy were also excluded as no TB outcome data could be 
obtained from these patients.  
 
Information regarding ART was poorly captured in the TB files. It was difficult to link 
patients in the TB clinic with registers in the ART clinic as numbers at both clinics 
were different. 
 
3.4.1.2.2 Study population at ART clinics 
In line with the guidelines of the DOH (DOH, 2010:23), all patients at the ART clinics 
were screened for TB at their baseline visit, prior to initiation of ART. Suspect TB 
patients (diagnosed by signs and symptoms) or those diagnosed by X-rays were 
referred to the TB clinic for further investigation. Patients with confirmed TB started 
TB treatment and were then referred back to the ART clinic for reassessment and 
commencement of ART. Patients then had to go to the TB clinic for TB treatment and 
the ART clinic for ART on separate days, unless the patient arranged with the clinic 
staff to adjust the appointments so that they coincided (DOH, 2010:23). 
 
Few data relating to TB had been captured in the ART files. Patients could not easily 
be traced back to the TB clinic because the patient numbers were different at each 
clinic, and these numbers were also not recorded. 
 
3.5  Specific sampling criteria 
 
3.5.1  Inclusion criteria 
TB clinic 
The study sampled the medical files of all adult patients: diagnosed with TB by symptoms, 
positive sputum smears and cultures and/or chest x-ray, entered onto the TB register, and 
treated at any of the selected sites 12 months prior to initiation of the study; and those 
aged 15 years and older. 
ART clinic 
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The study sampled the medical files of all adult patients: diagnosed with HIV, entered onto 
the ART register, and treated for TB at any of the selected sites for at least three months 
prior to initiation of TB treatment and those aged 15 years and older. 
 
3.5.2  Exclusion criteria 
TB clinic 
The study excluded the medical files of patients: aged less than 15 years; those who had 
more than one month’s TB treatment at a different institution and transferred to the study 
site to continue TB treatment and those treated for drug-resistant TB.  
 
ART clinic 
The study excluded the medical files of patients: aged less than 15 years; and those who 
had less than three months of ART at the time of commencing TB treatment. 
 
The study was aimed at investigating patients who potentially required second-line ART. 
These are a different population to patients who develop immune reconstitution 
inflammatory syndrome (IRIS) after initiating TB-HIV therapy, an important clinical problem 
that has been extensively studied. IRIS occurs in the first few weeks after initiating ART, 
and is rare after three months of ART. The rationale for excluding patients on less than 
three months ART treatment was therefore to ensure that IRIS patients were not included. 
The evaluation of childhood HIV and TB clinical management is distinct and different from 
that of adults, and was therefore not a focus of the study. Accordingly those aged less than 
15 years were excluded. 
 
3.5.3  Study sample  
When doing a study it may not be possible to access the entire population and findings 
may be based on a subset of participants (Goddard & Melville, 2004). This study used a 
retrospective, quantitative, cohort technique. The study sample was selected in the 
following manner: Having gained prior permission from the study sites the PI scheduled 
dates and times to be spent at each clinic. The PI accessed the clinic TB register, 
identified all TB patients and entered them onto a screening log. The files of eligible 
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patients were reviewed to ensure the data met the inclusion criteria of the study. Data of all 
patients who met the study criteria were entered into the data collection tool (Appendix 1). 
 
3.5.3.1  Study sample: TB clinic 
At the TB clinics, a total of 600 medical files were to be reviewed. This sample size was 
based on prior knowledge from a study conducted by the SAMRC. From the latter study, it 
was known that an estimated 15% of all TB patients in the eThekwini Region were on 
ART. With a 95% confidence level and 5% margin of error, a sample size of 589 was 
required, at a power of 90% to estimate this proportion. 
 
The 600 files to be reviewed were divided equally between the three study sites. The 
actual total of 579 (96.5%) files was reviewed. Older files, that had been poorly archived, 
were not easily traced. Difficulties in accessing these files resulted in the sample size 
falling short of the intended 600 files. The file review was completed within the time frame 
of January 2010 and May 2010. The researcher maintained this timeframe at all sites as 
this ensured availability of files and access to information. 
 
3.5.3.2 Study sample: ART clinic 
The primary end point of the study at the ART clinics was combined HIV and TB 
favourable outcomes at six months. Based on prior knowledge from the study conducted 
by the SAMRC (Dilraj & Rustomjee, 2009)    it was estimated that 75% of patients would 
have had a favourable TB outcome (cure or completion) and of these 66% would have had 
a favourable HIV outcome (undetectable viral load). Therefore, it was estimated that with a 
combined favourable HIV and TB outcome of 50% and a 7% error, a sample size of 532 
was required for 95% confidence at a power of 90%.  
 
A total of 1245 ART files were reviewed across the three study sites. Of these, 501 were 
identified with TB. In line with the inclusion criteria (section 3.4.1.2) the researcher further 
reviewed these files to extract data for only those (n=42) that had three months or more of 
ART at the time of commencement of TB treatment.  
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3.6  Data collection tool 
Data were extracted using a structured data collection tool (Appendix 1). The tool was 
developed by the researcher, based on the findings from the literature and 
recommendations from experts in the field (Dr Pym, MRC KZN, and Dr Marais, 
Stellenbosch University) as well as advice from a statistician at SAMRC KZN). 
 
This tool was pre-printed, and quality control and quality assurance of the completed data 
forms were undertaken by the researcher (as explained in section 1.11). The data from 
each patient file were entered manually onto a separate data form. Since data were 
collected from both the TB and ART clinics, using the same data collection tool, the 
researcher differentiated the tool by colour coding and using white or yellow paper 
respectively. This was to ensure that the data from the separate clinics were not mixed. 
Completed data forms were filed per clinic site and kept in a locked cupboard in the 
researcher’s office.  
 
3.6.1 DEMOGRAPHIC profile 
Data were collected on the age and sex of all patients. The initial intent was also to collect 
data on ethnicity. The pilot test revealed that ethnicity was not being captured in the 
patient files, and it was not possible or ethical to determine ethnicity from names.  
 
3.6.2  HIV-related results 
This data included known HIV status, VCT and patients who did not want to be tested for 
HIV. Baseline CD4, viral loads and repeat tests data were also captured.  
 
3.6.3 ART  
Data included were the starting date and regimen of ART. These data helped to identify 
those patients who had three months or more of ART, prior to starting TB treatment. 
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3.6.4 SPUTUM results 
This data included all sputum TB smears and cultures that had been recorded. This 
information was used to determine baseline smears and outcome of smear results at two 
and three months of TB treatment. 
 
3.6.5 TB diagnosis 
This data captured the common diagnostic method used to detect and treat TB. Delays in 
turnaround time for sputum results from the National Health Laboratory Services may have 
resulted in delays in commencement of TB treatment. 
 
3.6.6  Previous TB 
This data outlined whether the patient had been previously diagnosed with TB and had 
received treatment. 
 
3.6.7  Current TB 
This data showed the dates of TB diagnoses and the start of TB treatment. It also showed 
the regimen used and any change in medication as well as the reason for changing 
medication. It also captured completion or default of treatment. 
 
3.6.8 OUTCOME 
Outcome data were collected to measure the TB treatment outcome at six months after 
the commencement of treatment. At this stage, the patient was assessed for completion of 
treatment, sputum smear conversion and TB symptoms resolved, for example, whether 
the X-ray was normal, and the patient was discharged from the TB clinic. HIV outcomes 
could not be measured as data on ART. Progress was not fully captured in patient files in 
both the TB and ART clinics. HIV outcome was to be measured using CD4 count and viral 
loads. These tests were either not both done or they were recorded inconsistently in 
patient files. 
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3.6.9  Pilot test 
A pilot test is a small-scale version of the major study. Unforeseen problems may arise 
during a study. By doing a pilot test, the researcher can identify and address relevant 
issues and make adjustments to ensure the smooth running of the actual study (Brink et 
al., 2005:54). 
 
Prior to the empirical phase, the tool was tested in order to validate its applicability. A small 
sample of patient files (15 files, representing 2% of the study population) was randomly 
selected. Five files were identified from the TB register in the past 6 months at time of pilot 
study. The file that could be located was used to capture the data from each site. The data 
were captured electronically by the SAMRC-designated data capturer.  
 
Based on the findings from the pilot test, some adjustments were made to the data 
collection tool. In the demography section, ethnicity was omitted as this was not being 
captured on the clinic files. The clinics serve a multi ethnic community and it would be 
biased to determine ethnicity based on name alone. CD4 details were captured based on 
date rather than monthly interval as CD4 was not done at absolute specific dates. TB 
symptoms were omitted as it was not being collected on all patients and was not required 
for any of the outcome results. The sputum collection format was changed to capture data 
of two sputum samples and the interval was replaced by date as sputum samples were not 
collected at specific intervals (e.g. two weeks, three months, six months) , instead 
collected as client presented at the clinic. The outcome at six months was changed to 
represent the outcome that appeared on the patients file and TB registers. The manually 
captured data were entered into an electronic database (EpiData, version 3.3) by the 
researcher, and used by the statistician to test the data analysis method. The validation 
files and data were excluded from the empirical study. The manually captured data were 
entered into an electronic database (EpiData, version 3.3) by the researcher. The 
statistician used the database to test the data analysis method. The validation files and 
data were excluded from the empirical study.  
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3.7  Validity and reliability  
This was a retrospective study. There was no patient contact and therefore the data 
collection tool was not in the form of a questionnaire. The tool was designed to collect data 
from patients’ files that were required to meet the study objectives. The face and content 
validity of the data collection tool was validated by experts in the field as mentioned 
previously in section 3.8. The applicability of the tool was validated in the pilot test prior to 
the empirical phase in order to ensure that it captured all the required information to 
achieve the objectives of the study. Data yielded from the pilot test was used to validate 
the tool and to test the data analysis method. All the data were collected by the researcher 
who is a Registered Nurse with seven years of research experience. The researcher used 
the assistance of an experienced research fieldworker employed by the SAMRC. The 
fieldworker was used to trace and collect files from the clinics for data capture by the 
researcher. The fieldworker did not capture any data. Collection of the files of the study 
sample was systematic; it followed the sequence of the file numbers and the timeframe of 
January 2010 to May 2010 to ensure complete data were collected for all patients. Quality 
control and assurance (QC/QA) of the captured data was undertaken daily by the 
researcher. The data were compared and checked against registers and patient medical 
files. Missing data and errors were corrected immediately. A QC/QA check was also done 
by a qualified data encoder with many years of research experience. Missing data were 
marked and any errors or omitted information was brought to the researchers attention, 
and the respective corrections were made. Data were double-entered by the biostatistician 
to ensure reliability of data capture. 
 
3.8  Data collection  
The researcher undertook the data collection on her own as funding was limited and the 
researcher was capable of completing the task alone. Using the data collection tool, the 
data were extracted manually from the sampled files. Attention to collection of all files for 
the various samples was systematic to ensure complete data capture. All patient files at 
the selected clinics were reviewed from date of start of study to a period of one year prior 
to study. 
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3.9  Data management and analysis 
The collected data were captured into an electronic database (EpiData Version 3.3) by the 
data encoder. Double-entry was completed by the statistician who also verified and 
validated the data captured. There were few inconsistencies that were rectified by the 
researcher. The database which reflected the variables and categories of the data 
collection tool was presented to and approved by the statistician. 
  
The data were analyzed using STATA (version 11.0) with the assistance of the statistician 
from SAMRC KZN. The data were presented in tables for descriptive statistics. This was 
deemed the appropriate method due to the large number missing variables i.e. incomplete 
data entry in the patient medical files. Statistics reported were proportions and means and 
standard deviations. The analysis of categorical variables is presented using cross 
tabulations with frequencies and percentages reported.  Means and standard 
deviations were only used to summarize the age distribution of participants within each 
site. 
 
3.10  Conclusion  
Chapter 3 presented an in-depth description of the methodology employed in the study. 
The study used a retrospective cohort research design. Patients’ files were accessed, and 
data relevant to the study objectives were extracted and entered into a data collection tool. 
Data were extracted from the TB and ART registers and patients’ files. 
  
Data collection at the DOH facilities was made difficult by missing files, incomplete data in 
the files and poor correlation of data between TB register and patient files. The researcher 
was presented with many challenges that will be expanded upon in Chapter 5. However, 
despite these problems, sufficient data were obtained to effectively address the principal 
objectives of the study. 
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CHAPTER 4 
DATA ANALYSIS, INTEPRETATION AND DISCUSSION  
4.1  Introduction 
Chapter 4 presents, interprets, and discusses the results of the data analyzed for this 
study. The study was retrospective and quantitative in nature. The data analysis was 
descriptive, and the results are presented in the form of frequency tables and proportions. 
 
4.2 Presentation and discussion of the study findings 
The results of the study will be presented and discussed by site and for the total cohort. 
The results will be discussed for the TB and HIV cohort under the following sections: 
demographic data, age, gender, HIV and ART analysis, HIV related tests, diagnosis, TB 
treatment and outcome. Results are reported only for those data that were found to be 
statistically significant (p≤0.05).  
 
4.2.1 TB clinic cohort 
A flow chart was used to show the breakdown of the cohort to give clarity on the type of TB 
and identify the number of TB cases initiating chemotherapy. The sample (N=579) is 
analyzed and depicted in Diagram 1.1 showing previously treated and new TB as well as 
the type of TB. 
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Diagram 1: Characteristics of TB clinic cohort in terms of type of TB and history of previous 
treatment 
  
The study sample (N=579) shows that 78.4% (454/579) of patients were newly diagnosed 
with TB, 20.6%. (119/579) had a previous episode of TB of which 3.4% (4/119) had extra 
pulmonary TB (EPTB). Of the new TB cases, 90.1% (409/454) had Pulmonary 
Tuberculosis (PTB) and 9.9% (45/454) had extra pulmonary TB. 
 
4.2.2  Demographic data 
The demographic data collected from the three research sites for the purpose of the study 
included gender and age. Ethnic group was not captured on patient files and therefore 
could not be used to determine ethnic distribution. The findings are presented in Tables 6 
and 7. 
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Table 7  Gender of patients by site: TB clinics 
Gender Site A 
N=212 
Site B 
N=162 
Site C 
N=205 
Total 
N=579 
Male n=109  
 (51.4%) 
n=82  
(14.2%) 
n=102 
(17.6%) 
293  
(50.6%) 
Female n=102  
 (48.1%) 
n=80  
 (13.8%) 
n=103  
(17.8%) 
285  
(49.2%) 
Missing Data n=1  
 (0.5%) 
0 0 1  
(0.2%) 
 
 
Table 8  Age of patients by site: TB Clinics 
Age Site A 
N=212 
Site B 
N=162 
Site C 
N=205 
Total 
N=579 
15-30 n=79 
(39.5%) 
n=54 
(27%) 
n=67 
(33.5%) 
200 
(34.5%) 
31-45 n=85 
(32.2%) 
n=82 
(31.1%) 
n=97 
(36.7%) 
264 
(45.6%) 
46-60 n=40 
(48.8%) 
n=16 
(19.5%) 
n=26 
(31.7%) 
82 
(14.2%) 
>60 n=6 
(20%) 
n=10 
(33.3%) 
n=14 
(46.7%) 
30 
(5.2%) 
Unknown n=2 
(66.7%) 
n=0 n=1 
(33.3%) 
3 
(0.5%) 
The demographic data of the sample show a relatively even distribution in gender. Total 
male were 50.6% (293/579) and female were 49.2% (285/579). Mean age is reflected at 
36 years across all sites. All ages from 15 years and above were included in the study.  
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4.2.3 HIV and ART analysis 
The primary TB objective was to determine the proportion of all TB patients in the study 
who had developed TB after three months or more of ART treatment. Therefore the TB 
analysis was further broken down in Diagram 2 to show the percentage of patients that 
developed TB after having had three months or more of ART treatment. 
 
Diagram 2:  TB Analysis showing percentage of patients that developed TB 3 months after ART 
 
Of all the medical files of TB patients reviewed, 71.3% (413/579) were HIV-positive. The 
HIV positive patients included those who knew their HIV status (Known positive) 51.6% 
(299/579) and those who tested positive 20.2% (117/579) and 16.4% (95/579) were 
negative at time of TB diagnosis. 12.3% (71/579) of the medical files had missing data and 
were categorized as unknown. These include those that did not have a HIV test or no 
record of test done or results in patient medical file. Of the 413 HIV-positive patients, 
33.2% (137/413) had commenced ART, 47% (194/413) were not on ART and the ART 
status was unknown for 20% (82/413). Nearly 50% (68/137) patients on ART had 
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commenced ART prior to TB diagnosis and treatment and 13.9% (19/137) had 
commenced ART after TB. Of the 137 patients on ART, 36.5% (50/137) had no records in 
the patient files of whether ART were commenced prior to TB or after. The notes usually 
just indicated ‘ART commenced’. Of the 68 who commenced ART prior to TB diagnosis 
and treatment, 29.4% (20/68) had commenced ART more than 3 months prior to acquiring 
TB, 22.1% (15/68) commenced ART less than 3 months prior to TB, and 48.5% (33/68) 
were unknown due to missing data in patient files. The 48.5% of missing data could have 
significantly increased the number of patients that commenced ART prior to TB. This was 
a retrospective study where data were only collected from the TB register and patient 
medical files, missing data could not be rectified or filled in, but had to be captured as 
missing information. The biggest challenge for this study was that of missing data. 
Information that was current and required for the treatment of the patients’ current 
problems, i.e. TB, were captured fully and fields related to HIV, CD4, viral loads and ART 
were often left blank or filled incompletely. In the TB clinic all TB information was 
completed fully but HIV and ART information was sparse and vice-versa in the ART clinic. 
 
4.2.3.1  HIV-related tests 
These tests included HIV rapid tests, ELISA when available, as well as CD4 and viral 
loads. 
 
4.2.3.1.1  HIV status 
Table 9 shows the HIV status of TB patients at the time of TB diagnosis. The table 
reflects HIV testing and status by site and in total. 
 
Stellenbosch University  http://scholar.sun.ac.za
CHAPTER 4:  DATA ANALYSIS, INTERPRETATION AND DISCUSSION 
 
50 
Table 9  HIV status at the time of TB diagnosis 
HIV Test done Site A 
N=212 
 
Site B 
N=162 
 
Site C 
N=205 
 
Total 
N=579 
 
 
Yes 
 
n=78 
(36.6%) 
 
n=50 
(23.5%) 
 
n=85 
(39.9%) 
 
n=213 
(36.9%) 
 
No 
 
n=21 
(38.9%) 
 
 n= 6 
(11.1%) 
 
n=27 
(50%) 
 
n=54 
(9.3%) 
Known positive  
n=111 
(37.1%) 
 
n=104 
(34.8%) 
 
n=84 
 (28.1%) 
 
n=299 
 (51.6%) 
 
Unknown 
 
  n= 2 
(15.4%) 
 
  n= 2 
(15.4%) 
 
 n= 9 
(69.2%) 
 
 n=13 
 (2.2%) 
 
The findings reveal that of all patients, 51.6% (299/579) was aware of their HIV 
positive status at the time of TB diagnosis, and 46.1% (267/579) were not tested. Of 
these267, 79.8% (213/267) agreed to be tested and 20.2% (54/267) were not tested. 
Those not tested included those that refused to be tested and defaulters. Of this data 
there was 2.2% (13/579) that had missing data and is shown as unknown in Table 9. 
Missing data refers to data that were not recorded on the patients’ medical files. 
 
In keeping with the emphasis on HIV Counselling and Testing (HCT) at local clinics 
and institutions, analysis of the sample shows that more patients knew their HIV 
status than those that did not know their status but agreed to testing after 
counselling. However 20.2 % (54/579) of patients did not know their status and had 
not been tested. The numbers that were not tested included patients who refused 
testing, needed time to think about VCT, and did not go back to be tested. Of the 213 
that tested, 54.9% (117/213) were HIV positive, 44.6% (95/213) negative, and 1 
missing data (no data in patients’ file). The South African Government launched a 
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major HIV counselling and testing campaign (HCT) in 2010 (South African 
Government Information. 2010). Since implementation in 2010, the HCT campaign 
has had a notable impact on the availability and uptake of HIV testing and treatment.  
 
4.2.3.1.2  CD4 status 
In 2009, the government raised the CD4 treatment initiation threshold from 200 to 
350 cells/mm3, to be in line with the latest WHO guidelines (DOH 2010:4).Initiating 
treatment below 350 cells/mm3was implemented on the basis that it would improve 
the mortality rate amongst those that were HIV-infected. This change was 
implemented and substantiated by the SAPIT trial (Abdool Karim et al. 
2010)mentioned in Chapter 2. 
 
However, raising the threshold neglects the fact that most patients start treatment 
long after becoming eligible as shown in the data above. Patients generally start 
treatment only when they become seriously ill especially after presenting with TB 
symptoms or other serious AIDS associated conditions. Of the 579 TB patients 47% 
(194/579) were not on ART at time of TB diagnosis and 14% (19/194) of those that 
were on ART commenced after being diagnosed with TB. The following results on 
CD4, ART start date, and TB start date illustrate the late start of ART. Table 9 
outlines baseline CD4 done for all patients who were HIV positive. Baseline CD4 for 
the purpose of the study was identified as the first CD4 test done. It was not 
restricted to any timeframe. 
 
Stellenbosch University  http://scholar.sun.ac.za
CHAPTER 4:  DATA ANALYSIS, INTERPRETATION AND DISCUSSION 
 
52 
Table 10: Testing for CD4 lymphocyte count 
CD4 Test Done Site A 
N=158 
 
Site B 
N=112 
Site C 
N=141 
 
Total 
N=411 
 
 
Yes 
 
n=127 
(40.8%) 
 
n=80 
(25.7%) 
 
n=104 
(33.5%) 
 
n=311 
(75.7%) 
 
No 
 
n= 6 
(37.5%) 
 
n= 8 
(50%) 
 
n= 2 
(12.5%) 
 
n=16 
(3.9%) 
 
Unknown 
 
n= 25 
(29.8%) 
 
n= 24 
(28.6%) 
 
n= 35 
(41.6%) 
 
n= 84 
(20.4%) 
 
Of all the TB patients, 53.7% (311/579) had CD4 tests recorded at baseline (that is first 
CD4 test done), 2.8% (16/579) did not and 29% (168/579) had an unknown CD4 count. 
Unknown included missing data (incomplete notes) in patient case notes. Written notes 
were minimal and when possible CD4 results and comments on whether CD4 was done or 
not were captured from notes. The baseline CD4 count for those tested is tabulated in 
Table 10 by site to show the percentage of patients at the various levels of CD4 ranging 
from below 50 cells/mm3 to greater than 350 cells/mm3, at time of TB diagnosis. 
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Table 11: CD4 lymphocyte count results  
CD4 Site A 
N=95 
Site B 
N=72 
Site C 
N=95 
Total 
N=262 
<50 n=12 
(34.3%) 
n=9 
(25.7%) 
n=14 
(40%) 
n=35 
(13.4%) 
50-99 n=16 
(39%) 
n=7 
(17.1%) 
n=18 
(43.9%) 
n=41 
(15.6%) 
100 - 199 n=28 
(39.4%) 
n=18 
(25.4%) 
n=25 
(35.2%) 
n=71 
(27.1%) 
200-350 n=20 
(29%) 
n=25 
(36.2%) 
n=24 
(34.8%) 
n=69 
(26.4%) 
>350  n=19 
(41.3%) 
n=13 
(28.3%) 
n=14 
(30.4%) 
n=46 
(17.5%) 
 
‘Test done’ in Table 9 shows 311 but the above breakdown only reflects 262. The reason 
for this difference is that 49 of the 311 files had missing results. That means the question 
‘was CD4 done’ in the patient medical files stated ‘yes’ but there was no results recorded 
in the patient medical files. Of 262 files, 13.4% (35/262) had CD4 below 50 cells/mm3, 
15.6% (41/262) were between 50 and 99, 27.1% (71/262) between 100 and 199, 26.4% 
(69/262) between 200 and 350 and 18% (46/262) had cd4 above 350 cells/mm3. The 
proportion of patients with CD4 count less than 200/350cells/mm3at time of TB diagnosis 
(secondary objective) was 37.3% (216) of 579 or as a percentage of those that had CD4 
done was 69.5% (216) of 311.  
 
4.2.4  Diagnosis 
As per DOH guidelines (DoH, 2010:18), diagnosis of TB and commencement of treatment 
can be based on various forms of diagnosis rather than on sputum results alone. Table 6 
gives an overview of the method of TB diagnosis of 579 patients. Type of diagnosis was 
analyzed on total sample size and not per clinic. 
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Table 12: Diagnosis method of tuberculosis 
X-Ray Mantoux Sputum Smear Sputum Culture Other 
n=300 
 (51.8%) 
n=1 
(1%) 
n=216 
 (37.5%) 
n=22 
 (3.7%) 
n=35 
(6%) 
 
The common method for TB diagnosis was X-rays as shown in table 12, 51.8% (300/ 579) 
were diagnosed with TB based on X-rays and treatment commenced prior to sputum 
results, 37.5% (216/579) on sputum smears, 3.7% (22/579) on sputum culture as sputum 
smears were negative or indeterminate and 1% (1) on Mantoux. The 35(6%) results that 
are shown as ‘other’ include diagnoses by means of biopsies, ultrasound, pleural 
aspiration, and scans. These diagnoses are used to diagnose extra pulmonary TB. A study 
done by Y. Hanifa showed that ‘CXR improved sensitivity substantially and allowed rapid 
treatment initiation’ and  suggested that it should be routine, where available, pending 
better point-of-care diagnostics(Hanifa, Fielding, Charalambous, et al., 2012:1252). 
 
4.2.4.1  Baseline smear and culture results. 
According to DOH guidelines each patient should produce two sputum samples for 
diagnosis (DOH, 2010: 18). The specimen is usually an early morning and a random spot 
specimen. Based on either positive specimen results treatment may be commenced. Two 
specimens were not collected in all cases. Also we must take into consideration that 
diagnosis of TB and treatment is not only based on positive smear results. A smear is a 
diagnostic tool used to determine if a patient has TB. According to Dorland’s Medical 
Dictionary (Dorland, 1901) a sputum specimen is spread on a glass slide, stained, washed 
in acid solution and examined to detect acid fast bacilli (AFB) in a specimen. According to 
WHO (WHO, 2010), the revised definition of a new sputum smear-positive pulmonary TB 
case is based on the detection of acid fast bacilli (AFB+) in at least one sputum sample in 
countries with a well functioning external quality assurance (EQA) system . The 
breakdown shown in Table 7 is smear and culture for specimen 1 and 2.  
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Table 13: Sputum AFB smear and culture results 
Smear Positive Negative Unknown Total 
1 n=210 
 (36.3%) 
n=323 
(55.8%) 
n=46 
(7.9%) 
N=579 
2 n=88 
(15.2%) 
n=205 
(35.4%) 
n=286 
49.4%) 
N=579 
Culture     
1 n=26 
(70.3%) 
n=11 
(29.7%) 
0 N=37 
2 n=3 
 (100%) 
0 0 N=3 
 
The results shown in Table 13 are based on the first sputum specimen (Smear 1) collected 
from the patient. Of all the TB patients 36.3% (210/579) had at least one acid fast bacilli 
(AFB+) in at least one sputum sample. All results recorded were either Positive or Positive 
(+, ++, +++). Smears for sample one, 55.8% (323/579) were negative, and 7.9 % ( 46/579) 
had an unknown result. For sample two, 15.2% (88/579) were positive smear, 35.4% 
(205/579) were negative and 49.4% (286/579) of results were unknown. The category 
‘unknown’ includes missing data, unrecorded results, sputum not collected, or sputum 
collected after TB treatment had commenced. Not all specimens had cultures done. In line 
with policy (DOH, 2009: 21) a culture may be requested if there are indeterminate smear 
results or if diagnosis is made on X-ray and smear results are negative. As a result the 
breakdown of the culture results in Table 12 is not reflective of the entire sample (579). 
Only 6.4% (37) had cultures done on smear 1. Of these, 89.2% (33/37) were culture 
positive and 10.8% (4/37) were negative. Only 3 (0.5%) of smear 2 had cultures done and 
all 3(100%) cultures were positive. 
 
4.2.5 TB Treatment 
Once a patient is diagnosed for TB the patient is commenced on TB treatment and the 
duration and medication is based on whether the TB is new (first diagnosis of TB) or old 
(previous TB infection or treatment for more than a month with chemotherapy).  
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4.2.5.1  Previous TB 
The data collected on previous TB revealed 95% (113/119) patients were treated for TB 
previously. The other 5% (6/119) can be accounted for as unknown or missing data. 
Previous TB data are not being fully captured by the clinic staff. Most often just a date and 
if treatment was taken is recorded. This again shows that significance of data capture is 
given to current condition and previous history is being ignored or seen as insignificant.  
 
4.2.5.2  Current TB 
All of the patients were commenced on TB treatment on diagnosis of TB, of which 76% 
(441/579) completed treatment and15.4% (89/579) had defaulted treatment. Defaulters 
included those people that defaulted treatment and when traced was found to be 
deceased. 8.5% (49/579) had missing or incomplete data in patient files. 
 
Streptomycin is prescribed for patients that have had previous TB (DoH 2009: 36). The 
prescription of streptomycin for patients who have had previous TB varies at each site. If a 
patient reports to have had previous Streptomycin, any allergies to Streptomycin or 
refuses daily injections then Streptomycin is omitted. Therefore, as per data collected, only 
37.8% (45/119) previous TB patients received Streptomycin.  
 
Pyridoxine (Vitamin B6) 50mg daily is suggested for patients taking isoniazid to prevent 
peripheral neuritis however it may not be given routinely. It should be given to TB patients 
who are alcohol abusers, pregnant, diabetic or epileptic (DOH, 2009: 39). Complete details 
on Pyridoxine were not collected as prescription and issue of pyridoxine was not properly 
recorded in patients’ files. Recording in patient chART were very sparse and often 
important information was omitted, as a result data could not be collected. Based on 
observation by the PI often pre-printed information in patient files are completed e.g. the 
regimen, but information that needs to be written in e.g. Pyridoxine, is omitted. This is the 
reason for large chunks of missing data from patient files. 
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4.2.5.3  Outcome 
Outcome of TB treatment is assessed after six months of TB treatment based on the 
smear results, chest X-rays or completion of TB treatment (DOH, 2009: 41). The following 
definitions are used to describe the outcome of TB treatment: 
 
Cured - A patient who was initially sputum smear-positive and who was sputum smear-
negative in the last month of treatment and on at least one previous occasion. 
Completed treatment  - A patient who completed treatment but did not meet the criteria for 
cure or failure. This definition applies to sputum smear-positive and sputum smear-
negative patients with pulmonary TB and to patients with extrapulmonary disease. 
Died - A patient who died from any cause during treatment. 
Failed - A patient who was initially sputum smear-positive and who remained sputum 
smear-positive at month 5 or later during treatment. 
Defaulted - A patient whose treatment was interrupted for two consecutive months or 
more. 
Not evaluated/Other - A patient whose treatment outcome is not known. 
Cured - A patient who was cured or who completed treatment. 
Table 14 shows the outcome after six months of TB treatment. 
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Table 14: TB outcome after six months of TB treatment 
Outcome 
Site A 
N= 210 
Site B 
N=161 
Site C 
N=205 
Total 
N=579 
Cured 
n=79 
(39.9%) 
n=76 
(38.4%) 
n=43 
(21.7%) 
 
n=198 
(34.2%) 
Treatment 
Completed 
n=74 
(30.1%) 
n=63 
(25.6%) 
n=109 
(44.3%) 
 
n=246 
(42.5%) 
Defaulted 
n=46 
(51.7%) 
n=11 
(12.3%) 
n=32 
(36%) 
n=89 
(15.4%) 
Treatment Failure 0 0 0 
0 
Deceased 
n=7 
(20.6%) 
n=6 
(17.6%) 
n=21 
(61.8%) 
n=34 
(5.9%) 
Other 
n=4 
(33.4%) 
n=5 
(41.6%) 
n=3 
(25%) 
n=12 
(2%) 
 
Of all the medical files reviewed of patients on TB treatment, 34.2% (198/579) were cured, 
and 42.5% (246/579) had completed TB treatment. In total 76.7% (444/579) had 
successfully completed six months of treatment, 15.4% (89/579) had defaulted treatment 
and 5.9% (34/579) died. The other 2% (12/579) included unknown outcome due to 
incomplete information on patient chART and those that treatment was on-going at time of 
data collection. A set timeframe of 12 months was allocated thus ensuring patients 
commenced on treatment would have completed treatment and there would be outcome 
results. However due to defaulting, treatment is extended and sometimes restarted as a 
result treatment was still on-going at time of data collection. Treatment could be extended 
up to 18 months or even two years when retreating or relapse of TB as seen in patient 
case files. 
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4.2.6 ART cohort 
The primary end point of the study was combined HIV and TB favourable clinical and 
treatment outcomes at six months. It was estimated that 75% of patients would have had a 
favourable TB outcome (cure and completion) and of these 66% would have had a 
favourable HIV outcome (undetectable viral load). Therefore it was estimated that with a 
combined favourable HIV and TB outcome of 50% and a 7% error, a sample size of 532 
medical files was required for a 95% confidence at a power of 90%. 
 
Based on the above assumption the researcher was to identify 532 patients in the ART 
clinic that had developed TB and data to be collected of those that had ART for three 
months or more at time of TB diagnosis. After the pilot study and random overviews of the 
ART clinics at the three sites it was realized that this will not be possible. The researcher 
instead reviewed patient files at the three sites between the period of January and May 
2010, the same period that was used to collect all of the TB data at the TB clinics.  
 
The researcher reviewed a total of 1245 patient medical files across the three sites. 
Patients’ medical files were identified from the TB register and systematically extracted 
and reviewed for the period of January 2010 to May 2010. At two of the three clinics  all 
files for this period were reviewed as the filing system and registers were systematic and 
easily accessible. At one clinic this was not possible. This site serves a larger community, 
however the researcher only managed to access 353 files. Files were being used daily and 
return of files to the filing room had a poor turnaround time. Also there was a poor filing 
system which made access and locating files difficult. Table 10 and Flow Chart 3 below 
gives a breakdown of what was obtained from these sites. 
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Table 15: ART data per site 
 
Site A 
N=353 
Site B 
N=435 
Site C 
N=457 
Total 
N=1245 
TB 
n=204 
(40.8%) 
n=135 
(26.9%) 
n=162 
(32.3%) 
n=501 
(40.2%) 
No TB 
n=110 
(20.1%) 
n=220 
(40.3%) 
n=216 
(39.6%) 
n=546 
(43.9%) 
UNK 
n=39 
(19.7%) 
n=80 
(40.4%) 
n=79 
(39.9%) 
n=198 
(15.9%) 
 N=204 N=135 N=162 N=501 
TB Prior to ART 
n=164 
(38.2%) 
n=114 
(26.6%) 
n=151 
(35.2%) 
n=429 
(85.6%) 
TB 0-3 mths after 
ART 
n=12 
(40%) 
n=11 
(36.7%) 
n=7 
(23.3%) 
n=30 
(6%) 
TB after 3 mths of 
ART 
N=28 
(14%) 
N=10 
(7%) 
N=4 
(2%) 
42 
(8.4%) 
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Diagram 3. ART Clinic Analysis. 
 
Of all the medical files of patients on ART between January and May 2010 reviewed, 
40.2% (501/1245) had TB and 43.9% (546/1245) had not had TB. 15.9% (198/145) of files 
reviewed had missing data and were recorded as ‘unknown’. Of the 40.2% (501) of 
patients who had TB, 6% (30/501) were diagnosed with TB within three months of 
commencing ART, and 8.4% (42/501) after three months or more of ART. 
 
In order to identify the primary objective ‘patients that were newly diagnosed with TB three 
months or more after commencing ART’, the 8.4% (42) patients who fitted this criterion 
were further analyzed. This breakdown is shown in Table 16. 
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Table16: Details of patients diagnosed with TB after three months or more of ART. 
 Site TB Extra-TB Total 
 New Previous Unknown   
 N=16 N=8 N=13 N=5 N=42 
A n=12 
 (42.85%) 
n=4 
 (14.3%) 
n =9 
(32.1%) 
n=3 
(10.7%) 
N=28 
(66.7%) 
 
B n=3 
(30%) 
n=2 
(20%) 
n=3 
 (30%) 
n=2 
(20%) 
n=10 
 (23.8%) 
C n=1 
 (25%) 
n =2 
 (50%) 
n=1 
(25%) 
n=0 N=4 
(9.5%) 
 
Amongst the patients that had TB after 3months or more of ART, 38.1% (16/42) were new 
TB cases, 19% (8/42) had previous TB, 30.9% (13/42) had missing data (Unknown) and 
11.9 % (5/42) had extrapulmonary TB. 
 
4.2.6.1  Gender  
Of the patients that had TB three months or more after commencing ART, 61.9% (26/42) 
where women and 38.1% (16/42) were men.  
 
4.2.6.2 HIV status at the time of TB diagnosis 
97.6% (41/42) were known positive (i.e. they knew their HIV status at time of TB diagnosis 
and treatment). The other 2.4% (1/42) was counselled and tested positive. 
 
4.2.6.3  CD4 and viral load 
CD4 tests were done on 92.8% (39/42) patients that had TB after three months or more of 
ART therapy and the other 7.1% (3/42) had missing data (unknown). Data for viral load 
were recorded for only 9.5% (4/42) patients. 
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Table 17 shows the percentage of patients at the various levels of CD4 ranging from below 
50 cells/mm3 to greater than 350 cells/mm3 at time of TB diagnosis. 
 
Table 17:   CD4 levels and patient percentage. 
CD4 Total 
  
<50 N=9 
(21.4%) 
50-99 N=8 
 (19%) 
100 - 199 N=20 
(47.7%) 
200-350 N=2 
 (4.8%) 
>350 N=3 
 (7.1%) 
Total 42 
 
Of the 42 patients that had TB after 3 months or more of ART therapy 21.4% (9/42) had 
CD4 counts below 50cells/mm3,19% (8/42) were between 50 and 99cells/mm3, 47.7% 
(20/42) had CD4 between 100 and 199, 4.8% (2/42) had CD4 between 200 and 
350cells/mm3 and 7.1% (3/42) had CD4 above 350cells/mm3. 
 
4.2.6.4  Outcome 
TB outcome for the 42 patients that had TB after three months or more of ART therapy 
could not be measured as TB outcome was not recorded in patients ART files. On rare 
occasion a note was made on completion of TB medication. No dates or actual outcome 
was recorded. As mentioned previously, only data that were specific to that clinic that was 
required to treat the patients’ current condition were captured. The lack of coordination of 
the TB and HIV outcomes between clinics is a reflection of the poor integration of HIV and 
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TB services. It was therefore not possible to derive a combined HIV-TB outcome measure 
as articulated in the protocol.  
 
4.3  Conclusion 
Chapter 4 presented and discussed the results of the study, using several tables and flow 
chART highlighting the primary objectives and giving breakdowns of collected data that 
represent the secondary objectives. The analysis brings to the fore many challenges and 
gaps that are apparent when patients conditions are treated separately, i.e. TB is 
managed but HIV status and ART management are ignored. Also the findings show that 
there is an uptake of ART only after TB diagnosis. Patients after HCT are not followed up 
for CD4 counts and start of ART. As a result patients present at the clinic only when they 
are very ill with TB symptoms and have very low CD4 counts. Table 5 shows 216 (82.4%) 
patients had CD4 below 350 cells/mm3 at time of TB diagnosis and 147 (56%) had CD4 
counts below 200 µcells. 
 
Chapter 5 will highlight challenges and limitations of the study and draw final conclusion of 
data that was analyzed. 
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CHAPTER 5 
CONCLUSIONS AND RECOMMENDATIONS 
5.1  Introduction 
Chapter 5 draws conclusions based on the specific study objectives as outlined in Chapter 
3. In addition there are some more general conclusions derived from the experience of 
carrying out the survey in DOH clinics that relate to burden of TB as well as TB/HIV co-
infection, and from the state of clinical services providing for these conditions. In addition 
since both the TB clinics and ART clinics were visited certain conclusions can be drawn 
concerning the integration of the two services.  
 
Field research at the clinics revealed a lack of adequate data recorded in patient medical 
files and poor filling systems. Consequently, large amounts of laboratory results and 
findings were not filed or recorded. For this reason, the study objectives were only partly 
realizable. The very lack of adequate data highlights the need to integrate TB and HIV 
services. This will be explained in more detail below. In addition some recommendations 
for the provision of integrated TB/HIV services are offered. These recommendations are in 
line with the current National Tuberculosis and ART Guidelines presented by the South 
African government. 
 
5.2  Achievement of the study aims and objectives 
The aims of the study were to determine what proportion of all patients with TB were 
established on ART at the time of TB diagnosis, and what their clinical and treatment 
outcomes were in different public health care facilities in the eThekwini region of KZN. 
Underlying this aim was the requirement for a better understanding of the potential need to 
treat these patients with second-line ART.  
 
5.2.1  Objective 1 
The first objective was to determine the proportion of all patients with TB who were 
established on ART at the time of TB diagnosis. The findings concluded that out of 137 
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patients who received ART: 49.6% (68/137) had commenced ART prior to TB diagnosis 
and treatment; 29.4% (20/68) had commenced ART more than three months prior to 
acquiring TB; and 22.1% (15/68) commenced ART less than three months prior to TB. 
However the above figures are not reflective of the desired objective due to missing data in 
patient medical files. Thirty-three files (48.5%) had inadequate data on ART treatment. 
 
However, it is possible to gain an idea of the proportion of all TB patients who are on ART 
for more than three months at the time of TB diagnosis if one excludes the proportion of 
patients who have missing data. This obviously assumes that having a missing value is not 
associated with a particular variable. If this is done then one can determine that 81.3% 
(413/508) patients were HIV-positive.  
 
Of the 413 HIV positive patients, 137 were taking ART of which 49.6% (68/137) had 
initiated before starting TB therapy and 43% had done so for more than three months. This 
gives a figure of 11% of all TB patients who are on ART for more than three months at the 
time of TB diagnosis. This is a significant proportion of all TB patients and underlines how 
important it is to determine if these patients are failing ART therapy and therefore 
developing TB. If so these patients would need to be started on second-line ART therapy. 
 
5.2.2  Objective 2 
The second objective was to establish the clinical characteristics of patients established on 
ART who were newly diagnosed with TB. This objective was only partly achieved where 
clinical characteristics could be established for CD4 counts. However, there was much 
missing data in the patient medical files.  
Of the data available for the CD4 count it was established that:  
• 13.4 (35/262) had CD4 counts below 50-cells/mm3’; 
• 15.6 (41/262) were between 50 and 99;  
• 27.1% (71/262) were between 100 and 199;  
• 26.3 (69/262) were between 200 and 350; and 
• 17.6 (46/262) had CD4 counts above 350-cells/mm3.  
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The percentage of patients who had CD4 tests was 69.5% (216/311). It can be seen that 
patients who present with an opportunistic illness, in this instance TB, have their CD4 
tested only at baseline. Repeat CD4 tests were either not done or results not recorded. In 
order to determine the clinical characteristics of patients established on ART repeat CD4 
data is required at intervals to determine the improvement or regression of the CD4 count. 
It was therefore not possible to determine outcomes of therapy in terms of CD4 count. 
 
5.2.3  Objective 3 
The third objective was to evaluate the clinical management of patients established on 
ART who were newly diagnosed with TB. 
 
This objective was not possible to achieve because little or no data were recorded in the 
patient medical files with regards to the clinical management of ART in the TB patient files, 
and with regard to the clinical management of TB in the patients ART files. As mentioned 
in Chapter 4, only data relevant to managing the patients’ condition specific to the clinic 
were collected and entered into the files. At the TB clinic, all relevant TB data were 
collected and very few data on ART treatment were entered; only a basic ‘yes/no’ or a date 
was recorded. The opposite was relevant at the ART clinic: only data relevant to ART were 
collected. When a patient was diagnosed with TB or referred from the TB clinic for 
commencement of ART, only a note was recorded in the patients’ medical files.  
 
When a patient who had been established on ART (i.e. three months or more of ART) was 
diagnosed or suspected of having TB, the patient was referred to the TB clinic and a note 
was recorded on the ART file. There was no follow up information on confirmation of TB, 
commencement/completion of TB regimen or outcome of TB. Again lack of CD4 results or 
repeat CD4 counts not done made this objective less achievable. 
 
The lack of data was therefore the biggest challenge in meeting the objectives of the 
study. TB and ART clinics were separate from each other; separate files and numbers 
were kept for each patient. There was no cross reference of patient file numbers so there 
was no way of tracing patients between the clinics to update or collect missing data.  
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5.2.4  Objective 4 
The fourth objective was to evaluate the TB and HIV treatment outcomes of patients 
established on ART who developed TB. 
While TB outcomes could be measured, they could not be related to HIV outcomes. TB 
outcomes could not be measured against improvements in CD4 counts because TB 
patients could not be traced back to the ART clinic or vice versa.Of the 579 medical files 
reviewed for patients on TB treatment, 34.2% (198/579) were recorded as cured and 
42.5% (246/579) as TB treatment completed. In total out of all the TB patients 76.7% 
(444/579) had successfully completed their six months of treatment; 15.4% (89/579) had 
defaulted on their treatment; 5.9% (34/579) patients died; and outcomes were unknown for 
the remaining 2.1% (12/579) due to incomplete information on patients’ chART, or 
treatment had not yet been completed at the time of data collection.  
 
The above data provide a clear picture of successful outcomes of TB treatment despite its 
long duration of six months. However, it would be helpful to be able to associate the TB 
outcomes with ART treatment/outcomes in order to draw conclusions and make 
recommendations in respect of TB/HIV co-infection and the need to integrate TB/HIV 
services. 
 
Secondary outcomes for the TB cohort were more achievable than the HIV cohort as 
shown below. 
 
TB 
a. Proportion of patients who were smear positive on smear 1 was 3.62% (21/579) and 
on second smear was 15.2% (88/579). 
b. Proportion of patients tested for HIV was 86.7% (502/579), which included those that 
knew their status and those that were tested. 
c. Proportion of patients tested for HIV and CD4; was 75.7% (311/411). 
d. Proportion of patients with CD4 less than 200/350 depending on when ART were 
commenced as per the new DOH guidelines, was 69.5% (216/311). 
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e. Proportions of patients with favourable TB outcomes at two months (e.g. smear 
conversion): this was not achieved as sputum smear was not collected for all patients 
at a precise two-month interval. Any sample that was collected after the two-month 
interval was recorded as the two-month result. 
f. Proportion of patients on ART with viral loads and CD4 after diagnosis of TB, was 
31.5% (98/311). 
g. Proportion of patients on ART with a CD4 above 200 at time of TB diagnosis was 
14.8% (46/311).   
h. Proportion of patients with documented ART and TB treatment-adherence problems 
was 15.4% (89/579). 
 
HIV 
a. Proportion of patients on TB treatment who switch from first line ART therapy to 
second-line ART therapy: there was no documented evidence of this in the patients’ 
medical files. 
b. Proportion of patients whose CD4 was below 200 at time of TB diagnosis was 88.1% 
(37/42). 
c. Proportion of patients who had CD4 and viral loads within three months of TB 
diagnosis: no data were available in patients’ medical files of repeat CD4 or viral loads 
after TB. 
d. Proportion of patients with viral load undetected at time of TB diagnosis: no data were 
recorded in patients’ files of viral load results. 
e. Proportion of patient with increase in CD4 and decrease in viral load from baseline: no 
data were available to determine CD4 and viral load outcomes. 
f. Proportion of patients on ART with favourable TB outcomes at two and six months: TB 
outcomes were not recorded in patients’ ART medical file. 
g. Proportion of patients with favourable HIV outcomes as determined by undetectable 
viral loads at the end of TB treatment: no data were available. 
 
 
Stellenbosch University  http://scholar.sun.ac.za
CHAPTER 5:  CONCLUSIONS AND RECOMMENDATIONS 
 
70 
5.3  Limitations of the study 
The study was retrospective; data were collected from registers as well as patient medical 
files. The study was therefore subject to several limitations which may be classified and 
explained in the following way: 
 
5.3.1  Infrastructure 
Inadequate space for filing and archiving meant that patient medical files could not be 
located or were lost. PI used all available resources to trace and recover patient medical 
file to the best of her ability. 
 
5.3.2  Patient registers 
Both the TB and ART clinics kept registers but these were not completed. The TB register 
had ART, HIV, CD4 data missing and the ART register had TB information missing. These 
files could not be cross referenced to trace patients from the TB clinic to the ART clinic, or 
vice versa.  
 
5.3.3  Patients’ medical files 
Patients’ files consisted of pre-printed forms aimed at collecting relevant TB information. 
These forms only established: whether the patient is on ART, the start date of ART 
treatment and the CD4 count. This information was often not completed. The same lack of 
data applies in the ART clinic. Where TB data were required, the form was often left blank. 
This was the reason for the large gap of missing data in the analysis. Where ever possible 
the researcher gathered as much data from the patients’ medical files.  
 
It was not possible to derive a combined HIV and TB outcome due to the large amount of 
missing data in the patient medical files. The TB clinic did not capture ART data and 
management and the ART clinic did not capture TB data and management despite the pre 
printed files and documents that contained question pertaining to ART or TB. The lack of 
recorded data about ART in the TB clinic and TB in the ART clinic is a reflection of poor 
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integration of HIV and TB services and a result contributing to suboptimal management of 
the co-infection. 
 
5.3.4  Access to files at study sites 
All the study sites were very busy DOH clinics. This meant that files were either being 
used or were not filed, thus accessing the files was challenging. The PI continuously 
followed up on outstanding files to ensure adequate data were collected.  
 
From the above outcomes it is evident that due to the lack of data it is difficult to draw 
conclusions and make adequate recommendations. Being able to draw accurate 
information from clinics ensures that researchers can identify gaps and loopholes in our 
current management strategy and assist the DOH to better understand the HIV/TB co 
infection problem. Researchers may then confidently and without bias make 
recommendations and suggestions to properly address the crisis and contribute positively 
towards overcoming the current disease burden on our population. 
 
5.4  Recommendations 
Recommendations were made in regard to policies, management and practice, education 
and research. 
 
5.4.1  Recommendations from the literature 
From the literature review described in Chapter 2, it is known that there is a strong 
increase in TB in South Africa and that this increase is associated with HIV co-infection. 
“Infection with HIV is the most powerful known risk factor predisposing for Mycobacterium 
tuberculosis infection and progression to active disease, which increases the risk of latent 
TB reactivation 20-fold” (Pawlowski et al. 2012:np). Due to this and the fact that HIV 
continues to pose a threat, TB/HIV co-infection is a grave concern.  
 
Since gaining additional evidence from randomized controlled trials, observational studies, 
operational research and best practices from programmatic implementation of the 
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collaborative TB/HIV activities WHO recognized the need for integration of TB and HIV 
services and established a policy that emphasizes the need to establish mechanisms for 
delivering integrated TB and HIV services, preferably at the same time and location (WHO. 
2012:8).  
 
According to the WHO Guidelines (WHO, 2012), TB/HIV collaborated clinics need to 
achieve the following goals: 
a) To establish and strengthen the mechanisms of collaboration and joint management 
between HIV programmes and TB-control programmes for delivering integrated TB 
and HIV services, preferably at the same time and location; 
b) To reduce the burden of TB in people living with HIV, their families and communities 
by ensuring the delivery of Intensified TB case findings and Isoniazid preventive 
therapy and Infection control for TB and the early initiation of ART in line with WHO 
guidelines; 
c) To reduce the burden of HIV in patients with presumptive and diagnosed TB, their 
families and communities by providing HIV prevention, diagnosis and treatment. 
(WHO.2012:14) 
 
5.4.2 Recommendations from the study 
5.4.2.1  Policy 
From the data presented in Chapter 4 and observations made by the PI: those patients 
that developed TB prior to ART as well as those that were on ART and who were newly 
diagnosed with TB; needed to be referred to the ART and TB clinics respectively for 
commencement of co-treatment. 
 
The recommendation would be for DOH to draw up protocols and guidelines to implement 
and promote the integration of services. Integrating the two services would ensure a 
holistic approach to the HIV/TB co-infection epidemic. 
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Health care should always be aimed at holistic treatment of an individual. By separating 
the two infections and managing them separately other important factors are being 
neglected, for example psychosocial impact of co-infection and managing the intake of two 
medication regimens and their side effects. 
 
By integrating the services DOH can address a major issue that the health system is being 
faced with currently. That is the economic factor of the health system and its effects on the 
patient and the health care system. 
 
Having to visit two different clinics on two different dates can have financial implications 
and to a worker many constraints on getting so many days sick leave. Integrated services 
are easier for the patient to access in one visit. When health care is holistic and easily 
accessible it puts the patient into a comfort zone and the patient would want to access 
such a service. 
 
5.4.2.2  Management/practice 
It is important that TB clinics are able to initiate ART treatment and that ART clinics are 
able to screen and initiate TB treatment so that the services are integrated. This would 
mean that a client can access both services in one clinic. Staff can address issues related 
to both problems and give advice and refer as required. It promotes a holistic approach to 
the patients well being. Such integrated services will also help to reduce the challenge of 
defaulters. Once patients are started on TB treatment they may feel better and as a result 
if not educated well will feel there is no need to continue with ART and as a result default. 
Also the side effects of both drug regimens or the large intake of medication may cause a 
client to default treatment. As a result patients may have TB relapse or present with stage-
4 AIDS. 
 
Integrated services may lead to an increase in the uptake of TB and ART treatment due to 
the comprehensive management of the patient at one department. Patients that are 
referred to TB clinic may not go to the clinic due to, lack of knowledge, time and work 
constraints and inaccessibility of the clinic.  
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Integration will ensure that registers and notification of infections is not duplicated. 
Integrated patient records will ensure capture of accurate data for both infections. One of 
the challenges faced by the PI was the accessing of files. Due to space issues filling and 
archiving was poor. This may be eliminated in an integrated service as there will be no 
duplication of patient files, thus removing the strain on the filing systems and the need for 
space to keep two files for each patient. It will ensure easy access of patient information 
and data from which the institution can draw for monitoring and evaluation of its services. 
 
5.4.2.3  Education 
All nurses working at the clinics are Primary Health Care trained and able to identify and 
manage both infections, but due to specialisation and delegation only manage the infection 
that is specific to that clinic. All nurses should be able to deal with both infections on all 
levels. Nurses at both clinics need to be given refresher courses on the integrated 
management of HIV and TB. Nurses need to be constantly updated on the progress and 
outcomes of the integration of services. The importance of data collection and record 
keeping must be emphasized. With the roll out of Nurse Initiated and Management of 
ART(NIMART) all nurses should be afforded the training thus ensuring that nurses at the 
TB clinic can initiate ART rather than refer to the ART clinic for further management. 
 
Community awareness has mainly been focused on HIV and the uptake of ART. An 
extensive awareness campaign needs to be implemented to make the community aware 
of the TB/HIV co-infection and the importance of ensuring both infections are treated 
simultaneously. More emphasis and education of communities should be placed on TB 
and the importance of completion of TB treatment while continuing ART. 
 
5.4.2.4  Research 
Nurses must be afforded the opportunity to analyse data that is collected and taught how 
to interpret their analysis. This will give them the opportunity to understand the need for 
research and how to use outcome results to monitor and evaluate their service. Research 
results may also be used by nurses to make recommendations to the DOH and use 
evidence based arguments to improve their services.  
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Table 18 gives an outline of the recommendations in the various areas discussed above.  
 
Table 18: Outline of recommendations. 
Area Recommendations 
Policy 1. Draw policies for integration of services. 
2. Draw guidelines for implementation of integrated services. 
3. Draw guidelines for monitoring and evaluation of integrated 
services. 
gement and Practice. 1. Implement integrated services. 
2. Draw up integrated patient medical files. 
3. Ensure patient records are simple and user friendly to 
capture integrated data of both infections. 
4. Introduce integrated patient registers and notification. 
5. Introduce adequate filing and archiving systems for easy 
access and follow up. 
6. Implement monitoring and evaluation strategies to ensure 
adequate provision of integrated services. 
tion 1. Train all clinical staff in management of both infections. 
2. Train all clinical staff on data collection and reporting. 
3. Train all clinical staff in Good Clinical Practice. 
arch 1. DOH to build relationships with research organizations. 
Feedback from research conducted will assist in identifying 
issues and challenges. 
 
5.5  Conclusion 
Chapter 5 has explained to what extent the aim and objectives of the study were achieved. 
The study findings suggest that there are inadequacies in the current health system based 
on separate management of TB and HIV/AIDS, two serious diseases that are often found 
to co-exist. 
  
The findings of the study reflect the degree of service provision for TB and HIV as well as 
the loopholes in effectively managing or researching TB and HIV when these diseases are 
treated as separate entities. The PI recognizes there are certain limitations that presented 
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problems during the study. However, where possible such problems were accounted for 
and strategies were employed to minimize their potential impact, as in the case of missing 
data in patient files. In the latter case, there was an attempt to recover data from registers, 
patient case notes and laboratory results.  
 
The study reflects that there is a need for further research and data collection to determine 
the actual burden of the TB/HIV co-infection and to assess whether the introduction of 
TB/HIV integrated services significantly contributes to the reduction of HIV and TB rates. 
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    ARV/TB DATA 
   
Site Identification: ___ ___ ___            Reg.No _ _ _ _ _ _    Subject Initials: ______   
       
Study No:       -------------------             Clinic__________________ 
 
Signature ________________________                                                    Date ____/_______/_________ 1
 
Demographics:  
 
1.Gender: Male                Female   
 
 
2.Age 
_________yrs         
 
 
 
HIV/CD4 STATUS 
 
Date Unknown =Nk/Nk/Nk 
Unk = Unknown 
 
4.HIV Test Done :      
 Yes                     
  No                       
Known Positive   
UNK                    
 
 
  
 
5.If Yes, date collected:  _____ / _______ / _____                        
                                           (dd/mon/yyyy)                                                       
6.Results  
  Neg.                                          Pos  
7.CD4 Test Done :             Yes        No    Unk  
 
8.Viral Load Test Done :      Yes        No   Unk  
 
 
 
9.CD4/Viral Load 
 
Interval CD4 Viral Load 
 Date Results Date Results 
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    ARV/TB DATA 
   
Site Identification: ___ ___ ___            Reg.No _ _ _ _ _ _    Subject Initials: ______   
       
Study No:       -------------------             Clinic__________________ 
 
Signature ________________________                                                    Date ____/_______/_________ 2
     
     
1     
2     
3     
4     
Comments : 
 
 
 
 
 
 
 
10.ARV Therapy 
 
 ARV’s commenced     Yes     Comment : 
                                 No                                  
                                UNK         
TDF= Tenofovir  3TC= Lamuvidine  FTC= Emtracitabine  EFV=Efavirenz  NVP= Nevirapine  d4T= Stavudine 
AZT= Zidovudine  LPV/r= Lopinavir/Ritonavir. 
 
ARV Drug Start Date Stop Date Reason for 
Switch 
Comment 
TDF      
3TC     
FTC     
EFV     
NVP     
d4T     
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    ARV/TB DATA 
   
Site Identification: ___ ___ ___            Reg.No _ _ _ _ _ _    Subject Initials: ______   
       
Study No:       -------------------             Clinic__________________ 
 
Signature ________________________                                                    Date ____/_______/_________ 3
AZT     
Bactrim     
DDC     
LPV/R     
Other     
Unspecified ARV     
     
     
     
  
 
   
 
 
11.TB Diagnosis 
X-Ray                  
Sputum  Smear     
 
Sputum Culture    
CSF                    
Other                    Specify : 
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Site Identification: ___ ___ ___            Reg.No _ _ _ _ _ _    Subject Initials: ______   
       
Study No:       -------------------             Clinic__________________ 
 
Signature ________________________                                                    Date ____/_______/_________ 4
 
12.Sputum Collection 
 
Culture Done  Yes    No   UNK   
 
Visit Date Smear Culture DST HAIN 
  Specimen 
1 
Specimen 
2 
Specimen 
1 
Specimen 
2 
  
 
1 
       
 
2 
       
 
3 
       
 
4 
       
 
5 
       
 
6 
       
 
7 
       
 
8 
       
 
9 
       
 
10 
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    ARV/TB DATA 
   
Site Identification: ___ ___ ___            Reg.No _ _ _ _ _ _    Subject Initials: ______   
       
Study No:       -------------------             Clinic__________________ 
 
Signature ________________________                                                    Date ____/_______/_________ 5
12. TB History (Previous TB) 
 
Did the patient have previous TB  Yes     No  Unk  
 
Type of TB.                               
 
12.1 Pulmonary                   Yes                   NO                            
 
12.2 Extra Pulmonary           Yes                   No      
If12. 2 Identify (Tick Appropriate Condition) 
 
Lymph Nodes             
Kidney                       
Bone                         
Spine                          
Cardiac(Pericarditis)     
Abdomen (Peritonitis)   
Brain (Meningitis)         
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    ARV/TB DATA 
   
Site Identification: ___ ___ ___            Reg.No _ _ _ _ _ _    Subject Initials: ______   
       
Study No:       -------------------             Clinic__________________ 
 
Signature ________________________                                                    Date ____/_______/_________ 6
13.TB Therapy (Previous) 
 
TB Treatment  Yes    Comment: 
                      No           
                       Unk  
H=Isoniazid ,R= Rifampicin ,Z=Pyrizinamide ,E= Ethambutol,S=Streptomycin 
Outcome – Completed ,Defaulted  , Unknown            
TB DRUGS Start Date Stop Date Outcome Drug Resistance 
Isoniazid     
Rifampicin     
Pyrizinamide     
Ethambutol     
Streptomycin     
Pyridoxine     
Other     
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    ARV/TB DATA 
   
Site Identification: ___ ___ ___            Reg.No _ _ _ _ _ _    Subject Initials: ______   
       
Study No:       -------------------             Clinic__________________ 
 
Signature ________________________                                                    Date ____/_______/_________ 7
15. Current TB 
Current TB   
 
Yes      No    Unk  (If yes please tick new/old) 
Old    
New  
Unk   
 
Type of TB.                                
15.1 Pulmonary          Yes                   NO                            
 
15.2  Extra Pulmonary           Yes                   No      
 
If 15.2  Identify (Tick Appropriate Condition) 
 
Lymph Nodes             
Kidney                       
Bone                          
Spine                         
Cardiac(Pericarditis)     
Abdomen (Peritonitis)    
Brain (Meningitis)         
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
    ARV/TB DATA 
   
Site Identification: ___ ___ ___            Reg.No _ _ _ _ _ _    Subject Initials: ______   
       
Study No:       -------------------             Clinic__________________ 
 
Signature ________________________                                                    Date ____/_______/_________ 8
16.TB Therapy (Current) 
 
9.TB Treatment commenced    Yes   Comment:               
                       No 
                                                              Unk 
H=Isoniazid ,R= Rifampicin ,Z=Pyrizinamide ,E= Ethambutol,S=Streptomycin 
Outcome – Completed -1,Defaulted -2 , Unknown-3, Ongoing -4            
Regimen 1 Start Date Stop Date Outcome Drug Resistance 
Isoniazid     
Rifampicin     
Pyrizinamide     
Ethambutol     
Other(List)     
Multivitamin     
     
     
 
 
 
14.Weight 
Visit Date Weight 
 
Baseline 
  
 
1 
  
 
2 
  
 
3 
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Site Identification: ___ ___ ___            Reg.No _ _ _ _ _ _    Subject Initials: ______   
       
Study No:       -------------------             Clinic__________________ 
 
Signature ________________________                                                    Date ____/_______/_________ 9
 
4 
  
 
5 
  
 
6 
  
 
7 
  
 
8 
  
 
9 
  
 
10 
  
 
 
 
 
 
17.Outcome: 6 Months 
 
 
 
 
Cured                                           Date of Outcome --/--/---- 
Treatment Completed            
Treatment Defaulted                               Date of Last Visit  --/--/---- 
Treatment Failure                  
Deceased                                               Date of Death  --/--/---- 
Other                                      
If Other Explain: 
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